Biocept (BIOCQ) 10-Q 14 Nov 17 2017 Q3 Quarterly report Financial data

Document and Entity Information

Document and Entity Information - shares	9 Months Ended
	Sep. 30, 2017	Nov. 09, 2017
Document And Entity Information [Abstract]
Document Type	10-Q
Amendment Flag	false
Document Period End Date	Sep. 30, 2017
Document Fiscal Year Focus	2,017
Document Fiscal Period Focus	Q3
Trading Symbol	BIOC
Entity Registrant Name	BIOCEPT INC
Entity Central Index Key	1,044,378
Current Fiscal Year End Date	--12-31
Entity Filer Category	Smaller Reporting Company
Entity Common Stock, Shares Outstanding		30,258,743

Condensed Balance Sheets

Condensed Balance Sheets - USD ($)	Sep. 30, 2017	Dec. 31, 2016
Current assets:
Cash	$ 5,879,025	$ 4,609,332
Accounts receivable, net	1,133,372	128,969
Inventories, net	775,106	549,045
Prepaid expenses and other current assets	412,916	484,649
Total current assets	8,200,419	5,771,995
Fixed assets, net	2,919,796	1,806,331
Total assets	11,120,215	7,578,326
Current liabilities:
Accounts payable	1,593,048	960,486
Accrued liabilities	2,174,385	1,160,036
Supplier financings	121,043	75,691
Current portion of equipment financings	304,585	262,674
Current portion of credit facility, net	1,645,136	1,934,665
Total current liabilities	5,838,197	4,393,552
Non-current portion of equipment financings	950,123	778,643
Non-current portion of credit facility, net		1,123,001
Non-current portion of interest payable		227,177
Non-current portion of deferred rent	305,816	397,292
Total liabilities	7,094,136	6,919,665
Commitments and contingencies (see Note 11)
Shareholders’ equity:
Preferred stock, $0.0001 par value, 5,000,000 authorized; no shares issued and outstanding at December 31, 2016 and September 30, 2017.
Common stock, $0.0001 par value, 150,000,000 authorized; 17,499,397 issued and outstanding at December 31, 2016; 30,258,743 issued and outstanding at September 30, 2017.	3,026	1,750
Additional paid-in capital	193,606,087	174,292,781
Accumulated deficit	(189,583,034)	(173,635,870)
Total shareholders’ equity	4,026,079	658,661
Total liabilities and shareholders’ equity	$ 11,120,215	$ 7,578,326

Condensed Balance Sheets (Paren

Condensed Balance Sheets (Parenthetical) - $ / shares	Sep. 30, 2017	Dec. 31, 2016
Statement Of Financial Position [Abstract]
Preferred stock, par value	$ 0.0001	$ 0.0001
Preferred stock, shares authorized	5,000,000	5,000,000
Preferred stock, shares issued	0	0
Preferred stock, shares outstanding	0	0
Common stock, par value	$ 0.0001	$ 0.0001
Common stock, shares authorized	150,000,000	150,000,000
Common stock, shares issued	30,258,743	17,499,397
Common stock, shares outstanding	30,258,743	17,499,397

Condensed Statements of Operati

Condensed Statements of Operations and Comprehensive Loss (Unaudited) - USD ($)	3 Months Ended		9 Months Ended
	Sep. 30, 2017	Sep. 30, 2016	Sep. 30, 2017	Sep. 30, 2016
Income Statement [Abstract]
Net revenues	$ 1,111,411	$ 1,047,280	$ 4,073,437	$ 1,931,509
Costs and expenses:
Cost of revenues	2,487,054	1,876,288	6,985,213	5,020,649
Research and development expenses	856,698	600,613	2,455,947	2,044,968
General and administrative expenses	1,834,771	1,918,543	5,539,432	4,923,431
Sales and marketing expenses	1,675,852	1,278,455	4,701,030	3,875,063
Total costs and expenses	6,854,375	5,673,899	19,681,622	15,864,111
Loss from operations	(5,742,964)	(4,626,619)	(15,608,185)	(13,932,602)
Other income/ (expense):
Interest expense	(88,269)	(154,869)	(385,172)	(393,029)
Other income	12,804	38,412	51,216	115,236
Total other income/ (expense):	(75,465)	(116,457)	(333,956)	(277,793)
Loss before income taxes	(5,818,429)	(4,743,076)	(15,942,141)	(14,210,395)
Income tax expense	(2,877)		(5,023)	(2,053)
Net loss and comprehensive loss	$ (5,821,306)	$ (4,743,076)	$ (15,947,164)	$ (14,212,448)
Weighted-average shares outstanding used in computing net loss per share attributable to common shareholders:
Basic	29,605,953	8,370,691	25,816,181	7,549,663
Diluted	29,605,953	8,370,691	25,816,181	7,549,663
Net loss per common share:
Basic	$ (0.20)	$ (0.57)	$ (0.62)	$ (1.88)
Diluted	$ (0.20)	$ (0.57)	$ (0.62)	$ (1.88)

Condensed Statements of Cash Fl

Condensed Statements of Cash Flows (Unaudited) - USD ($)	9 Months Ended
	Sep. 30, 2017	Sep. 30, 2016
Cash Flows from Operating Activities
Net loss	$ (15,947,164)	$ (14,212,448)
Adjustments to reconcile net loss to net cash used in operating activities:
Depreciation and amortization	394,708	246,864
Inventory reserve	(22,431)	(40,708)
Stock-based compensation	1,232,149	1,164,979
Non-cash interest expense related to credit facility and other financing activities	23,983	60,951
Increase/ (decrease) in cash resulting from changes in:
Accounts receivable, net	(1,004,403)	(51,464)
Inventory	(203,630)	(107,538)
Prepaid expenses and other current assets	431,355	501,532
Accounts payable	508,176	991,846
Accrued liabilities	671,407	152,860
Accrued interest	71,417	58,684
Deferred rent	(52,143)	(22,839)
Net cash used in operating activities	(13,896,576)	(11,257,281)
Cash Flows from Investing Activities:
Purchases of fixed assets	(1,055,549)	(391,196)
Net cash used in investing activities	(1,055,549)	(391,196)
Cash Flows from Financing Activities:
Net proceeds from issuance of common stock and warrants	10,583,898	4,798,576
Proceeds from exercise of common stock warrants	7,498,535
Payments on equipment financings	(109,811)	(86,336)
Payments on supplier and other third-party financings	(314,270)	(427,934)
Payments on credit facility	(1,436,534)	(778,303)
Net cash provided by financing activities	16,221,818	3,506,003
Net increase/ (decrease) in Cash	1,269,693	(8,142,474)
Cash at Beginning of Period	4,609,332	8,821,329
Cash at End of Period	5,879,025	678,855
Cash paid during the period for:
Interest	285,260	282,142
Income taxes	$ 5,023	$ 2,053

Condensed Statements of Cash F6

Condensed Statements of Cash Flows (Unaudited) (Parenthetical) - USD ($)	Aug. 09, 2017	Mar. 31, 2017	Sep. 30, 2017	Sep. 30, 2016	Dec. 31, 2016	Dec. 31, 2015
Statement Of Cash Flows [Abstract]
Financed insurance premium through third party financing			$ 359,622	$ 434,475
Fixed assets purchased under capital lease obligations			362,729	755,458
Fixed assets with an aggregate net book value			34,491	270,377
Equipment financings with remaining outstanding balances				239,994
Purchases of fixed assets			$ 204,501	$ 8,637	$ 58,066	$ 64,300
Issuance of unregistered warrants to purchase shares of common stock	1,434,639	2,160,000
Exercise price of unregistered warrants	$ 1.50	$ 2.50
Unregistered warrants to purchase common stock, period	5 years	5 years
Issuance of unregistered warrants to purchase shares of common stock, grant date fair value	$ 1,500,000	$ 2,800,000
Offering fees and costs recorded within common stock issuance costs as an offset to additional paid in capital	$ 176,000	$ 728,000

The Company, Business Activitie

The Company, Business Activities and Basis of Presentation	9 Months Ended
	Sep. 30, 2017
Accounting Policies [Abstract]
The Company, Business Activities and Basis of Presentation	1. The Company, Business Activities and Basis of Presentation The Company and Business Activities The Company was founded in California in May 1997 and is an early stage molecular oncology diagnostics company that develops and commercializes proprietary circulating tumor cell, or CTC, and circulating tumor DNA, or ctDNA, assays utilizing a standard blood sample, or liquid biopsy. The Company’s current and planned assays are intended to provide information to aid healthcare providers to identify specific oncogenic alterations that may qualify a subset of cancer patients for targeted therapy at diagnosis, progression or for monitoring in order to identify specific resistance mechanisms. Often, traditional methodologies such as tissue biopsies are insufficient or unavailable to provide the molecular subtype information necessary for clinical decisions. The Company’s assays have the potential to provide more contemporaneous information on the characteristics of a patient’s disease compared with traditional methodologies such as tissue biopsy and radiographic imaging. Additionally, commencing in October 2017, the Company’s pathology program initiative provides the unique ability for pathologists to participate in the interpretation of liquid biopsy results, and is available to pathology practices and hospital systems throughout the United States. Further, the Company’s proprietary blood collection tubes, which allow for the intact transport of research use only liquid biopsy samples from regions around the world, are anticipated to be sold to laboratory supply distributor(s) commencing in 2018. The Company operates a clinical laboratory that is CLIA-certified (under the Clinical Laboratory Improvement Amendment of 1988) and CAP-accredited (by the College of American Pathologists), and manufactures cell enrichment and extraction microfluidic channels, related equipment and certain reagents to perform the Company’s diagnostic assays in a facility located in San Diego, California. CLIA certification and accreditation are required before any clinical laboratory may perform testing on human specimens for the purpose of obtaining information for the diagnosis, prevention, treatment of disease, or assessment of health. The assays the Company offers are classified as laboratory developed tests under the CLIA regulations. In July 2013, the Company effected a reincorporation to Delaware by merging itself with and into Biocept, Inc., a Delaware corporation, which had been formed to be and was a wholly-owned subsidiary of the Company since July 23, 2013. Basis of Presentation The financial statements and accompanying notes are prepared in accordance with accounting principles generally accepted in the United States of America. The unaudited condensed financial statements included in this Form 10-Q have been prepared in accordance with the U.S. Securities and Exchange Commission, or SEC, instructions for Quarterly Reports on Form 10-Q. Accordingly, the condensed financial statements are unaudited and do not contain all the information required by U.S. Generally Accepted Accounting Principles, or GAAP, to be included in a full set of financial statements. The balance sheet at December 31, 2016 has been derived from the audited financial statements at that date but does not include all of the information and footnotes required by GAAP for a complete set of financial statements. The audited financial statements for the year ended December 31, 2016, filed with the U.S. Securities and Exchange Commission, or SEC, with our Annual Report on Form 10-K on March 28, 2017 include a summary of our significant accounting policies and should be read in conjunction with this Form 10-Q. In the opinion of management, all material adjustments necessary to present fairly the results of operations for such periods have been included in this Form 10-Q. All such adjustments are of a normal recurring nature. The results of operations for interim periods are not necessarily indicative of the results of operations for the entire year. Certain prior period balances have been reclassified to conform to the current period presentation. Reverse Stock Split On September 27, 2016, the Company’s stockholders approved, and the Company filed, an amendment to the Company’s amended and restated certificate of incorporation to effect a one-for-three reverse stock split of the Company’s outstanding common stock, and to increase the authorized number of shares of the Company’s common stock from 40,000,000 to 150,000,000 shares. The one-for-three reverse stock split was effected September 29, 2016 Revenue Recognition and Related Reserves The Company's commercial revenues are generated from diagnostic services provided to physicians and billed to third-party insurance payers such as managed care organizations, Medicare and Medicaid and patients for any deductibles, coinsurance or copayments that may be due. The Company recognizes revenue in accordance with the provision of ASC 954-605, Health Care Entities—Revenue Recognition, which requires that four basic criteria must be met prior to recognition of revenue: (1) persuasive evidence of an arrangement exists; (2) delivery has occurred and title and the risks and rewards of ownership have been transferred to the client or services have been rendered; (3) the price is fixed or determinable; and (4) collectability is reasonably assured. Commencing on March 31, 2017, the Company recognizes commercial revenue related to billings for assays delivered and billed to Medicare and other third-party payers on an accrual basis when amounts that will ultimately be realized can be estimated upon delivery, whereby prior to March 31, 2017, the Company recognized revenues for its commercial diagnostic services on a cash basis as collected because the amounts ultimately expected to be received could not be estimated upon delivery due to insufficient collection history experience. The Company bills third-party payers on a fee-for-service basis at the Company’s list price and third-party commercial revenue is recorded net of contractual discounts, payer-specific allowances and other reserves. The Company’s development services revenues are supported by contractual agreements and generated from assay development services provided to entities, as well as certain other diagnostic services provided to physicians. Diagnostic services are completed upon the delivery of assay results to the prescribing physician, at which time the Company bills for the service. The Company’s gross commercial revenues billed are subject to estimated deductions for such contractual discounts, payer-specific allowances and other reserves to arrive at reported net revenues, which relate to differences between amounts billed and corresponding amounts estimated to be subsequently collected. These third-party payer discounts and sales allowances are estimated based on a number of assumptions and factors, including historical payment trends, seasonality associated with the annual reset of patient deductible limits on January 1 of each year, and current and estimated future payments. Specifically, the Company maintains four such reserves: the reserve for contractual discounts, the reserve for aged non-patient receivables, the reserve for estimated patient receivables, and the reserve for other payer-specific sales allowances. The reserve for contractual discounts relates to discounts to gross amounts billed to Medicare and contracted third-party payers to arrive at the deemed “allowed expense" amount covered by that payer. The Company’s contracted third-party commercial sales are recorded using an actual or contracted fee schedule at the time of sale, while estimated fee schedules are maintained for each non-contracted payer separately as part of other payer-specific sales allowances. Contractual discounts are recorded at the transaction level at the time of sale based on a fee schedule that is maintained for each contracted third-party payer. The Company periodically adjusts fee schedules for both contracted and non-contracted third-party payers based upon historical payment trends. The reserve for aged non-patient receivables reduces gross amounts billed to non-contracted third-party payers for amounts estimated to be collected according to the age of the outstanding balance. The reserve for estimated patient receivables reduces gross amounts billed to third-party payers for amounts estimated to be collected directly from individual patients, such as copayments, deductibles, or amounts otherwise designated as patient responsibility. The reserve for other payer-specific sales allowances relates to the amounts billed to non-contracted third-party payers that are estimated to not be covered by that specific payer’s coverage policies, as well as estimated necessary adjustments to gross amounts billed based on historical collection experience for a particular third-party payer unrelated to the age of outstanding balances. The estimates of amounts that will ultimately be realized from commercial diagnostic services require significant judgment by management. Patients do not enter into direct agreements with the Company that commit them to pay any portion of the cost of the tests in the event that they have not met their annual deductible limit under their insurance policy, if any, or if their insurance otherwise declines to reimburse the Company. Adjustments to the estimated payment amounts are recorded at the time of final collection and settlement of each transaction as an adjustment to commercial revenue. The estimation process used to determine third-party payer discounts and sales allowance has been applied on a consistent basis since March 31, 2017, and no significant subsequent adjustments have been necessary to increase or decrease these discounts and allowances as a result of changes in underlying estimates. The composition of the Company’s gross and net revenues recognized during the three and nine-months ended September 30, 2016 and 2017 is as follows: For the three months ended September 30, For the nine months ended September 30, 2016 2017 2016 2017 Commercial revenues recognized upon delivery $ - $ 3,602,194 $ - $ 12,298,790 Development services revenues recognized upon delivery 71,723 67,394 170,052 211,736 Commercial revenues recognized upon cash collection 975,557 102,234 1,761,457 1,158,277 Total gross revenues 1,047,280 3,771,822 1,931,509 13,668,803 Provisions for contractual discounts — (1,729,805 ) — (4,545,128 ) Provisions for aged non-patient receivables — (152,889 ) — (598,532 ) Provisions for estimated patient receivables — 27,909 — (90,931 ) Provisions for other payer-specific sales allowances — (805,626 ) — (4,360,775 ) Net revenues $ 1,047,280 $ 1,111,411 $ 1,931,509 $ 4,073,437 During the nine months ended September 30, 2017, the Company recorded $839,431 in nonrecurring net revenue as a result of recognizing revenue on an accrual basis commencing on March 31, 2017 associated with cases delivered on or prior to December 31, 2016, representing a corresponding decrease in net loss per common share of $0.03. The incremental net revenue as a result of recognizing revenue on an accrual basis commencing on March 31, 2017, or the total amount of net revenue recorded in excess of the amount of commercial cash collections, was $125,007 and $1,041,890 during the three and nine-months ended September 30, 2017, respectively, representing corresponding decreases in net loss per common share of zero and $0.04, respectively. A summary of activity in the Company’s gross and net accounts receivable balances, as well as corresponding reserves, during the nine months ended September 30, 2017 is as follows: Balance at Amounts Settlements Balance at December 31, Recognized Upon September 30, 2016 Upon Delivery Adjudication 2017 Accounts receivable, gross $ 128,969 $ 12,510,526 $ (5,649,054 ) $ 6,990,441 Reserve for contractual discounts — (4,545,128 ) 2,399,458 (2,145,670 ) Reserve for aged non-patient receivables — (598,532 ) 70,950 (527,582 ) Reserve for estimated patient receivables — (90,931 ) 1,072 (89,859 ) Reserve for other payer-specific sales allowances — (4,360,775 ) 1,266,817 (3,093,958 ) Accounts receivable, net $ 128,969 $ 2,915,160 $ (1,910,757 ) $ 1,133,372 Concentration of Risk Concentrations of credit risk with respect to revenues are primarily limited to geographies to which the Company provides a significant volume of its services, and to specific third-party payers of the Company’s services such as Medicare, insurance companies, and other third-party payers. The Company’s client base consists of a large number of geographically dispersed clients diversified across various customer types. The Company's third-party payers that represent more than 10% of total net revenues in any period presented, and their related net revenue amount as a percentage of total net revenues, during the three and nine-months ended September 30, 2016 and 2017 were as follows: For the three months ended September 30, For the nine months ended September 30, 2016 2017 2016 2017 Medicare and Medicare Advantage 63 % 45 % 54 % 41 % Blue Cross Blue Shield 15 % 16 % 12 % 17 % United Healthcare 19 % 14 % 19 % 12 % The Company's third-party payers that represent more than 10% of total net accounts receivable, and their related net accounts receivable balance as a percentage of total net accounts receivable, at September 30, 2017 were as follows: Blue Cross Blue Shield 27 % Medicare and Medicare Advantage 20 % United Healthcare 14 % Recent Accounting Pronouncements In May 2014, and as subsequently updated and amended from time to time, the Financial Accounting Standards Board, or the FASB, issued authoritative guidance that requires entities to recognize revenue when it transfers promised goods or services to customers in an amount that reflects the consideration to which the entity expects to be entitled to in exchange for those goods or services. This proposed guidance has been deferred and would be effective for annual reporting periods beginning after December 15, 2017, including interim periods within that reporting period, and may be applied retrospectively to each prior period presented or retrospectively with the cumulative effect recognized as of the date of adoption. Earlier application is permitted only as of annual reporting periods beginning after December 15, 2016, including interim periods within that reporting period. As the Company has not yet completed its final review of the impact of the new guidance but expects to during 2017, the Company has not determined whether the adoption of this guidance will have a material impact on its financial statements or disclosures. The Company is still evaluating disclosure requirements under the new guidance, and will continue to evaluate additional changes, modifications or interpretations to the guidance which may impact the current conclusions. The Company expects to adopt the new standard for the fiscal year beginning January 1, 2018 and anticipates that the modified retrospective application method will be applied. In July 2015, the FASB issued authoritative guidance requiring entities that do not measure inventory using the retail inventory method or on a last-in, first-out basis to record inventory at the lower of cost and net realizable value. Net realizable value is the estimated selling prices in the ordinary course of business, less reasonably predictable costs of completion, disposal, and transportation. This guidance is effective on a prospective basis for fiscal years beginning after December 15, 2016, including interim periods within those fiscal years. Early adoption is permitted. The Company adopted this guidance for the reporting period beginning January 1, 2017. The adoption of this guidance did not have a material impact on the Company’s financial statements or disclosures. In January 2016, the FASB issued authoritative guidance requiring, among other things, that certain equity investments be measured at fair value with changes in fair value recognized in net income, that financial assets and financial liabilities be presented separately by measurement category and form of financial asset on the balance sheet or the accompanying notes to the financial statements, that the prior requirement to disclose the method(s) and significant assumptions used to estimate the fair value that is required to be disclosed for financial instruments measured at amortized cost on the balance sheet be eliminated, and that a reporting organization is to present separately in other comprehensive income the portion of the total change in the fair value of a liability resulting from a change in the instrument-specific credit risk when the organization has elected to measure the liability at fair value in accordance with the fair value option for financial instruments. This guidance is effective for fiscal years, and interim periods within those years, beginning after December 15, 2017. Early adoption of the instrument-specific credit risk amendment is permitted. The Company expects to adopt this guidance for the fiscal year beginning on January 1, 2018, and does not anticipate that the adoption of this guidance will have a material impact on its financial statements or disclosures because the Company does not currently have any equity method investments. In February 2016, the FASB issued authoritative guidance requiring, among other things, that entities recognize the assets and liabilities arising from leases on the balance sheet under revised criteria, while the classification criteria for distinguishing between finance leases and operating leases are substantially similar to the classification criteria in the previous leases guidance. In transition, lessees and lessors are required to recognize and measure leases at the beginning of the earliest period presented using a modified retrospective approach. This guidance is effective for fiscal years beginning after December 15, 2018, including interim periods within those fiscal years. Early adoption is permitted. The Company anticipates that the adoption of this guidance will materially affect its statement of financial position and will require changes to its processes. The Company expects to adopt this guidance for the reporting period beginning on January 1, 2019, and has not yet made any decision on the method of adoption with respect to the optional practical expedients, but expects to during 2018. In March 2016, the FASB issued authoritative guidance clarifying that a change in the counterparty to a derivative instrument that has been designated as the hedging instrument does not necessarily require de-designation of that hedging relationship, provided that all other applicable hedge accounting criteria continue to be met. This guidance is effective on either a prospective basis or modified retrospective basis for fiscal years beginning after December 15, 2016, and interim periods within those fiscal years. Early adoption is permitted. The Company adopted this guidance for the reporting period beginning January 1, 2017. The adoption of this guidance did not have a material impact on the Company’s financial statements or disclosures. In March 2016, the FASB issued authoritative guidance requiring entities to assess whether contingent call (put) options that can accelerate the payment of principal on debt instruments are clearly and closely related to their debt hosts, and clarifies what steps are required when assessing whether the economic characteristics and risks of call (put) options are clearly and closely related to the economic characteristics and risks of their debt hosts. This guidance is effective on a modified retrospective basis for fiscal years beginning after December 15, 2016, and interim periods within those fiscal years. Early adoption is permitted. The Company adopted this guidance for the reporting period beginning January 1, 2017. The adoption of this guidance did not have a material impact on the Company’s financial statements or disclosures. In March 2016, the FASB issued authoritative guidance simplifying the accounting for stock compensation. This guidance, among other things, amends existing accounting and classification requirements primarily around income taxes, forfeitures, and cash payments associated with share-based payment awards to employees. This guidance is effective for fiscal years beginning after December 15, 2016, including interim periods within those fiscal years. Early adoption is permitted. The Company adopted this guidance for the reporting period beginning January 1, 2017. The adoption of this guidance did not have a material impact on the Company’s financial statements or disclosures. In August 2016, the FASB issued authoritative guidance clarifying the classification of certain cash receipts and cash payments in the statement of cash flows. This guidance is effective for fiscal years beginning after December 15, 2017, including interim periods within those fiscal years, on a retrospective transition method to each period presented. Early adoption is permitted. The Company currently intends to adopt this guidance for the fiscal year beginning on January 1, 2018, and does not anticipate that the adoption of this guidance will have a material impact on its financial statements or disclosures because the Company has not historically engaged in the transactions encompassed by the proposed guidance. In January 2017, the FASB issued authoritative guidance clarifying the definition of a business when evaluating transactions involving acquisitions or disposals of assets or businesses. This guidance is effective for fiscal years beginning after December 15, 2017, including interim periods within those fiscal years. Certain applications of this guidance are permitted for early adoption. The Company currently intends to adopt this guidance for the fiscal year beginning on January 1, 2018, and does not anticipate that the adoption of this guidance will have a material impact on its financial statements or disclosures because the Company has not historically acquired or disposed of material assets or businesses. In January 2017, the FASB issued authoritative guidance eliminating the “Step 2” requirement for an entity to determine the fair value of its assets and liabilities for goodwill impairment testing in the same manner that would be required for those assumed in a business combination. Instead, the amended guidance allows an entity to perform goodwill impairment testing by comparing the fair value of a reporting unit with its carrying amount. This guidance is effective for any goodwill impairment tests in fiscal years beginning after December 15, 2019, including interim periods within those fiscal years. Early adoption is permitted. The Company currently intends to adopt this guidance for the fiscal year beginning January 1, 2020, and does not anticipate that the adoption of this guidance will have a material impact on its financial statements or disclosures because the Company does not currently have any recorded goodwill. In February 2017, the FASB issued authoritative guidance clarifying the definition of the term “in substance nonfinancial asset” when accounting for transfers of financial and nonfinancial assets, and other matters concerning the transfer, sale and partial sale of nonfinancial assets to both consolidated entities and non-consolidated counterparties. This guidance is effective for fiscal years beginning after December 15, 2017, including interim periods within that reporting period. Early adoption is permitted. The Company currently intends to adopt this guidance for the fiscal year beginning on January 1, 2018, and does not anticipate that the adoption of this guidance will have a material impact on its financial statements or disclosures because the Company has not historically engaged in transfers, sales or partial sales of nonfinancial assets. In March 2017, the FASB issued authoritative guidance shortening the amortization period to the earliest call date for certain purchased callable debt securities held at a premium. This guidance is effective for fiscal years beginning after December 15, 2018, including interim periods within those fiscal years. Early adoption is permitted. The Company currently intends to adopt this guidance for the fiscal year beginning on January 1, 2019, and does not anticipate that the adoption of this guidance will have a material impact on its financial statements or disclosures because the Company does not currently hold any callable debt securities. In May 2017, the FASB issued authoritative guidance clarifying what modifications to a share-based payment award may be considered substantive, and therefore requiring the application of modification accounting. This guidance is effective for fiscal years beginning after December 15, 2017, including interim periods within those fiscal years. Early adoption is permitted. The Company currently intends to adopt this guidance for the fiscal year beginning on January 1, 2018, and does not anticipate that the adoption of this guidance will have a material impact on its financial statements or disclosures because the Company does not currently expect any significant modifications to outstanding share-based payment awards. In July 2017, the FASB issued authoritative guidance changing the classification analysis of certain equity-linked financial instruments (or embedded features) with down round features, whereby a down round feature no longer precludes equity classification when assessing whether the instrument is indexed to an entity’s own stock, and also clarifying existing disclosure requirements for equity-classified instruments. This guidance is effective for fiscal years beginning after December 15, 2019, and interim periods within fiscal years beginning after December 15, 2020. Early adoption is permitted. The Company currently intends to adopt this guidance for the fiscal year beginning on January 1, 2020, and does not anticipate that the adoption of this guidance will have a material impact on its financial statements or disclosures because the Company does not currently hold any significant financial instruments with down round features. In August 2017, the FASB issued authoritative guidance that expands and refines hedge accounting for both nonfinancial and financial risk components and align the recognition and presentation of the effects of the hedging instrument and the hedged item in the financial statements. This guidance is effective for fiscal years beginning after December 15, 2018, and interim periods within those fiscal years. Early application is permitted. The Company currently intends to adopt this guidance for the fiscal year beginning on January 1, 2019, and does not anticipate that the adoption of this guidance will have a material impact on its financial statements or disclosures because the Company does not currently hold any financial instruments accounted for as a hedging activity.

Liquidity and Going Concern Unc

Liquidity and Going Concern Uncertainty	9 Months Ended
	Sep. 30, 2017
Accounting Policies [Abstract]
Liquidity and Going Concern Uncertainty	2. Liquidity and Going Concern Uncertainty As of September 30, 2017, cash totaled $5.9 million and the Company had an accumulated deficit of $189.6 million. For the year ended December 31, 2016 and the nine month period ended September 30, 2017, the Company incurred net losses of $18.4 million and $15.9 million, respectively. At September 30, 2017, the Company had aggregate net interest-bearing indebtedness of $3.3 million, of which $2.4 million was due within one year, in addition to $3.4 million of other non-interest bearing current liabilities. In February 2016, the Company signed a firm, non-cancelable, and unconditional commitment in an aggregate amount of $1,062,500 with a vendor to purchase certain inventory items, payable in minimum quarterly amounts of $62,500 through May 2020, under which $625,000 remained outstanding at September 30, 2017 (see Note 11). These factors raise substantial doubt about the Company’s ability to continue as a going concern for the one-year period following the date that these unaudited condensed financial statements were issued. The accompanying unaudited condensed financial statements have been prepared assuming that the Company will continue as a going concern. The unaudited condensed financial statements do not include any adjustments to reflect the possible future effects on the recoverability and classification of assets or the amounts and classification of liabilities that may result from the possible inability of the Company to continue as a going concern. While the Company is currently in the commercialization stage of operations, the Company has not yet achieved profitability and anticipates that it will continue to incur net losses for the foreseeable future. Historically, the Company’s principal sources of cash have included proceeds from the issuance of common and preferred stock, proceeds from the exercise of warrants to purchase common stock, proceeds from the issuance of debt, and revenues from laboratory services. The Company’s principal uses of cash have included cash used in operations, payments relating to purchases of property and equipment and repayments of borrowings. The Company expects that the principal uses of cash in the future will be for continuing operations, hiring of sales and marketing personnel and increased sales and marketing activities, funding of research and development, capital expenditures, and general working capital requirements. The Company expects that, as revenues grow, sales and marketing and research and development expenses will continue to grow, albeit at a slower rate and, as a result, the Company will need to generate significant growth in net revenues to achieve and sustain income from operations. In May 2015, the SEC declared effective a shelf registration statement filed by the Company. The shelf registration statement allows the Company to issue any combination of its common stock, preferred stock, debt securities and warrants from time to time for an aggregate initial offering price of up to $50 million, subject to certain limitations for so long as the Company’s public float is less than $75 million. A public offering of the Company’s common stock and warrants to purchase its common stock closed on May 4, 2016, pursuant to which the Company received net cash proceeds of approximately $4.3 million (see Note 3). Subsequent to the closing of this offering on May 4, 2016, no warrants sold in this offering have been exercised, with approximately $4.5 million in gross warrant proceeds remaining outstanding and available to be exercised at $3.90 per share until their expiration in May 2021. A second offering of the Company’s common stock was effected under this shelf registration statement on March 28, 2017, the closing of which occurred on March 31, 2017, pursuant to which the Company received net cash proceeds of approximately $8.6 million (see Note 3). In a concurrent private placement, the Company sold unregistered warrants to purchase up to 2,160,000 shares of the Company’s common stock that closed concurrently with the March 31, 2017 offering of common stock sold pursuant to this shelf registration statement. Subsequent to the closing of the sales of these unregistered warrants, no warrants sold have been exercised, with $5.4 million in gross warrant proceeds remaining outstanding and available to be exercised at $2.50 per share until their expiration in October 2022. The specific terms of additional future offerings, if any, under this shelf registration statement would be established at the time of such offerings. A public offering of the Company’s common stock and warrants to purchase its common stock was effected under an underwriting agreement dated October 14, 2016 between the Company, Roth Capital Partners, LLC and Feltl and Company, Inc., as underwriters named therein, the closing of which occurred on October 19, 2016, pursuant to which the Company received net cash proceeds of approximately $9.0 million (see Note 3). Subsequent to the closing of this offering, cash proceeds of approximately $7.5 million have been received from the exercise of warrants sold in this offering, while approximately $3.2 million in gross warrant proceeds remain outstanding and available to be exercised at $1.10 per share until their expiration in October 2021. Pursuant to a common stock and warrant purchase agreement dated August 9, 2017 between the Company and Ally Bridge LB Healthcare Master Fund Limited, or Ally Bridge Management’s Plan to Continue as a Going Concern In order to continue as a going concern, the Company will need, among other things, additional capital resources. Until the Company can generate significant cash from operations, including assay revenues, management’s plans to obtain such resources for the Company include proceeds from offerings of the Company’s equity securities or debt, or transactions involving product development, technology licensing or collaboration. Management can provide no assurances that any sources of a sufficient amount of financing will be available to the Company on favorable terms, if at all.

Sales of Equity Securities

Sales of Equity Securities	9 Months Ended
	Sep. 30, 2017
Equity [Abstract]
Sales of Equity Securities	3. Sales of Equity Securities On December 21, 2015, the Company entered into a common stock purchase agreement with Aspire Capital Fund, LLC, or Aspire Capital, which committed to purchase up to an aggregate of $15.0 million of shares of the Company’s common stock over the 30-month term of the common stock purchase agreement. On November 4, 2016, the Company voluntarily terminated this common stock purchase agreement. In May 2015, the SEC declared effective a shelf registration statement filed by the Company. The shelf registration statement allows the Company to issue any combination of its common stock, preferred stock, debt securities and warrants from time to time for an aggregate initial offering price of up to $50 million, subject to certain limitations for so long as the Company’s public float is less than $75 million. Pursuant to an exclusive placement agent agreement dated April 25, 2016 between the Company and H.C. Wainwright & Co., LLC, and a securities purchase agreement dated April 29, 2016 between the Company and the purchasers signatory thereto, a public offering of 1,662,191 shares of the Company’s common stock and warrants to purchase up to an aggregate of 1,163,526 shares of common stock was effected under this registration statement at a combined offering price of $3.00. All warrants sold in this offering have a per share exercise price of $3.90, are exercisable immediately and expire five years from the date of issuance. The estimated grant date fair value of these warrants of approximately $2.0 million was recorded as an offset to additional paid-in capital upon the closing of this offering. Pursuant to an underwriting agreement dated October 14, 2016 between the Company, Roth Capital Partners, LLC and Feltl and Company, Inc., as underwriters named therein, a public offering of 9,100,000 shares of the Company’s common stock and warrants to purchase up to an aggregate of 9,100,000 shares of common stock was effected at a combined offering price of $1.10. The estimated grant date fair value of these warrants of approximately $5.2 million was recorded as an offset to additional paid-in capital upon the closing of this offering. All warrants sold in this offering Pursuant to a common stock and warrant purchase agreement dated August 9, 2017 between the Company and Ally Bridge, an offering of 1,466,667 shares of the Company’s common stock and warrants to purchase up to an aggregate of 1,434,639 shares of common stock was effected at a combined offering price of $1.50 per unit for total gross proceeds to the Company of $2.2 million. Subsequent to the closing of this offering, no additional cash proceeds had been received from the exercise of warrants sold in this offering. As such, the total increase in capital as a result of the sale of the common stock and warrants has been approximately $2.0 million after deducting $0.2 million of associated costs incurred, which were offset against these proceeds under applicable accounting guidance.

Fair Value Measurement

Fair Value Measurement	9 Months Ended
	Sep. 30, 2017
Fair Value Disclosures [Abstract]
Fair Value Measurement	4. Fair Value Measurement The estimated fair value of the credit facility entered into with Oxford Finance LLC in April 2014, or the April 2014 Credit Facility, at September 30, 2017 approximated its carrying value, which was determined using a discounted cash flow analysis. The analysis considered interest rates of instruments with similar maturity dates, which involved the use of significant unobservable Level 3 inputs. Other Fair Value Measurements As of the closing of the Company’s March 31, 2017 offering, the estimated grant date fair value of $1.31 per share associated with the warrants to purchase up to 2,160,000 shares of common stock issued in this offering, or a total of approximately $2.8 million, was recorded as an offset to additional paid-in capital, and was estimated using a Black-Scholes valuation model with the following assumptions: Stock price $ 2.13 Exercise price $ 2.50 Expected dividend yield 0.00 % Discount rate-bond equivalent yield 1.93 % Expected life (in years) 5.00 Expected volatility 80.0 % As of the closing of the Company’s August 9, 2017 offering, the estimated grant date fair value of $1.03 per share associated with the warrant to purchase up to 1,434,639 shares of common stock issued in this offering, or a total of approximately $1.5 million, was recorded as an offset to additional paid-in capital, and was estimated using a Black-Scholes valuation model with the following assumptions: Stock price $ 1.39 Exercise price $ 1.50 Expected dividend yield 0.00 % Discount rate-bond equivalent yield 1.81 % Expected life (in years) 5.00 Expected volatility 100.0 %

Balance Sheet Details

Balance Sheet Details	9 Months Ended
	Sep. 30, 2017
Organization Consolidation And Presentation Of Financial Statements [Abstract]
Balance Sheet Details	5. Balance Sheet Details The following provides certain balance sheet details: December 31, September 30, 2016 2017 Fixed Assets Machinery and equipment $ 2,728,468 $ 2,938,281 Furniture and office equipment 143,726 147,976 Computer equipment and software 620,582 1,526,482 Leasehold improvements 517,968 550,246 Financed equipment 1,559,690 1,922,418 Construction in process 169,896 7,481 Total fixed assets, gross 5,740,330 7,092,884 Less accumulated depreciation and amortization (3,933,999 ) (4,173,088 ) Total fixed assets, net $ 1,806,331 $ 2,919,796 Accrued Liabilities Accrued interest $ 20,776 $ 324,406 Accrued payroll 168,727 477,889 Accrued vacation 364,953 503,380 Accrued bonuses 422,868 625,682 Accrued sales commissions 77,844 48,390 Current portion of deferred rent 67,085 106,418 Accrued other 37,783 88,220 Total accrued liabilities $ 1,160,036 $ 2,174,385

April 2014 Credit Facility

April 2014 Credit Facility	9 Months Ended
	Sep. 30, 2017
Debt Disclosure [Abstract]
April 2014 Credit Facility	6. April 2014 Credit Facility On April 30, 2014, the Company received net cash proceeds of approximately $4,898,000 pursuant to the execution of the April 2014 Credit Facility with Oxford Finance LLC. Upon the entry into the April 2014 Credit Facility, the Company was required to pay the lender a facility fee of $50,000 in conjunction with the funding of the term loan. The April 2014 Credit Facility is secured by substantially all of the Company’s personal property other than its intellectual property. Amounts due to Oxford Finance LLC under the April 2014 Credit Facility are callable before maturity by the lender under certain subjective acceleration clauses of the underlying agreement, including changes deemed to be materially adverse by the lender. The term loan under the April 2014 Credit Facility bears interest at an annual rate equal to the greater of (i) 7.95% or (ii) the sum of (a) the three-month U.S. LIBOR rate reported in the Wall Street Journal three business days prior to the funding date of the term loan, plus (b) 7.71%. The term loan bears interest at an annual rate of 7.95%. The Company was required to make interest-only payments on the term loan through August 1, 2015. The outstanding term loan under the April 2014 Credit Facility began amortizing at the end of the applicable interest-only period, with monthly payments of principal and interest being made by the Company to the lender in consecutive monthly installments following such interest-only period. The term loan under the April 2014 Credit Facility matures on July 1, 2018. Under the original terms of the underlying agreement, the Company is also required to make a final payment to the lender equal to 5.5% of the original principal amount of the term loan funded. At its option, the Company may prepay the outstanding principal balance of the term loan in whole but not in part, subject to a prepayment fee of 1% of any amount prepaid. On June 30, 2016, the Company entered into an amendment of the April 2014 Credit Facility. This amendment required the Company to make interest-only payments on the term loan from July 1, 2016 through September 30, 2016, and also requires an additional final payment of $50,000 to the lender. The terms of the amendment require the amortization of the outstanding amount due under the term loan to commence at the end of the applicable interest-only period, with monthly payments of principal and interest, in arrears, being made by the Company to the lender in consecutive monthly installments following such interest-only period. Additionally, pursuant to the amendment the aggregate outstanding principal amount of the Company’s permitted indebtedness, consisting of capitalized lease obligations and purchase money indebtedness outstanding at any time, was increased to $1.2 million. The June 30, 2016 amendment of the April 2014 Credit Facility was accounted for as a modification of debt under applicable accounting guidance. On June 28, 2017, the Company entered into an amendment of the April 2014 Credit Facility whereby the aggregate outstanding principal amount of the Company’s permitted indebtedness was increased to $3.0 million. The April 2014 Credit Facility includes affirmative and negative covenants applicable to the Company and any subsidiaries created in the future. The affirmative covenants include, among others, covenants requiring the Company to maintain its legal existence and governmental approvals, deliver certain financial reports and maintain insurance coverage. The negative covenants include, among others, restrictions on transferring collateral, incurring additional indebtedness, engaging in mergers or acquisitions, paying dividends or making other distributions, making investments, creating liens, selling assets, and suffering a change in control, in each case subject to certain exceptions. The April 2014 Credit Facility also includes events of default, the occurrence and continuation of which provide Oxford Finance LLC, as collateral agent, with the right to exercise remedies against the Company and the collateral securing the term loan under the April 2014 Credit Facility, including foreclosure against the Company’s properties securing the April 2014 Credit Facility, including its cash. These events of default include, among other things, the Company’s failure to pay any amounts due under the April 2014 Credit Facility, a breach of covenants under the April 2014 Credit Facility, insolvency, a material adverse change, the occurrence of any default under certain other indebtedness in an amount greater than $250,000, and a final judgment against the Company in an amount greater than $250,000. A warrant to purchase up to 17,655 shares of the Company’s common stock at an exercise price of $14.16 per share with a term of 10 years was issued to Oxford Finance LLC on April 30, 2014. Issuance costs of $102,498 associated with the term loan under the April 2014 Credit Facility were recorded as a discount to outstanding debt as of the closing date, resulting in net proceeds of $4,897,502. The estimated fair value of the warrant issued of $233,107 was also recorded as a discount to outstanding debt as of the closing date. The discounts and other issuance costs are amortized to interest expense utilizing the effective interest method over the underlying term of the loan, with total unamortized discounts of $78,408 and $54,405 remaining at December 31, 2016 and September 30, 2017, respectively. The effective annual interest rate associated with the April 2014 Credit Facility was 13.87% at both December 31, 2016 and September 30, 2017. As of September 30, 2017, total remaining principal payments of $498,132 and $1,201,409 were due under the April 2014 Credit Facility during the fiscal years ending December 31, 2017 and 2018, respectively.

Equipment Financings

Equipment Financings	9 Months Ended
	Sep. 30, 2017
Capital Lease Obligations [Abstract]
Equipment Financings	7. Equipment Financings The Company leases certain laboratory equipment under arrangements accounted for as capital leases and classified as equipment financings. The financed equipment is depreciated on a straight-line basis over periods ranging from 5 to 7 years. The total gross value of fixed assets capitalized under such financing arrangements was $1,559,690 and $1,922,418 at December 31, 2016 and September 30, 2017, respectively. Total accumulated depreciation related to financed equipment was approximately $525,000 and $681,000 at December 31, 2016 and September 30, 2017, respectively. Total depreciation expense related to financed equipment was approximately $40,000 and $52,000 for the three months ended September 30, 2016 and 2017, respectively. Total depreciation expense related to financed equipment was approximately $93,000 and $160,000 for the nine months ended September 30, 2016 and 2017, respectively. Fixed assets purchased totaling $362,729 during the nine months ended September 30, 2017 were recorded as equipment financings. The aggregate weighted average effective annual interest rate related to the equipment financings was 13.18% and 13.79% at December 31, 2016 and September 30, 2017, respectively, and the maturity dates on such outstanding arrangements range from June 2018 to September 2024. The following schedule sets forth the remaining future minimum lease payments outstanding under financed equipment arrangements, as well as corresponding remaining sales tax and maintenance obligation payments that are expensed as incurred, due within each respective fiscal year ending December 31, as well as the present value of the total amount of remaining minimum lease payments, as of September 30, 2017: Maintenance Minimum and Sales Tax Lease Obligation Payments Payments 2017 $ 79,763 $ 8,954 2018 338,273 58,355 2019 313,529 68,925 2020 277,291 54,768 2021 267,665 48,802 Thereafter 522,397 88,313 Total payments 1,798,918 328,117 Less amount representing interest (544,210 ) — Present value of payments $ 1,254,708 $ 328,117 At September 30, 2017, the present value of minimum lease payments due within one year was $304,585. On September 15, 2017, and as amended on October 17, 2017, the Company executed an equipment financing commitment with a third-party lender for total proceeds to the Company of $150,848, which was funded by the lender on November 2, 2017. Under the terms of the amended equipment financing agreement, which was accounted for as a sale-leaseback transaction, fixed assets previously purchased by the Company with aggregate gross and net book values of approximately $167,000 and $156,000, respectively, were granted as a security interest to the third-party lender, with the principal balance plus annual interest of 10.24% to be repaid in 36 equal monthly installments through November 2020 for a total of $175,814.

Stock-Based Compensation

Stock-Based Compensation	9 Months Ended
	Sep. 30, 2017
Disclosure Of Compensation Related Costs Sharebased Payments [Abstract]
Stock-Based Compensation	8. Stock-Based Compensation Equity Incentive Plans The Company maintains two equity incentive plans: the Amended and Restated 2013 Equity Incentive Plan, or the 2013 Plan, and the 2007 Equity Incentive Plan, or the 2007 Plan. The 2013 Plan includes a provision that shares available for grant under the Company’s 2007 Plan become available for issuance under the 2013 Plan and are no longer available for issuance under the 2007 Plan. On July 25, 2016, the Company’s Board of Directors approved an amendment to the 2013 Plan to reserve 333,333 shares of the Company’s common stock exclusively for the grant of stock awards to employees who have not previously been an employee or director of the Company, except following a bona fide period of non-employment, as an inducement material to the individual’s entering into employment with the Company, as defined under applicable Nasdaq Listing Rules. At the Company’s annual meeting of stockholders held on May 2, 2017, the Company’s stockholders approved amendments to the 2013 Plan, which included an increase in the number of non-inducement shares of common stock authorized for issuance under the 2013 Plan by 2,500,000. As of September 30, 2017, under all plans, a total of 3,522,955 non-inducement shares were authorized for issuance, 2,712,157 non-inducement stock options and restricted stock units, or RSUs, were issued and outstanding, and 638,487 non-inducement shares were available for grant. As of September 30, 2017, a total of 333,333 inducement shares were authorized for issuance, 133,049 inducement stock options and RSUs were issued and outstanding, and 175,284 inducement shares were available for grant under the 2013 Plan. Stock Options A summary of stock option activity for the nine months ended September 30, 2017 is as follows: Weighted Average Weighted Remaining Number of Average Exercise Contractual Shares Price Per Share Term in Years Outstanding at December 31, 2016 896,662 $ 8.80 8.5 Granted 1,711,196 $ 1.49 Exercised — Cancelled/forfeited/expired (123,572 ) $ 5.13 8.7 Outstanding at September 30, 2017 2,484,286 $ 3.93 8.9 Vested and unvested expected to vest at September 30, 2017 2,267,826 $ 4.16 8.8 The intrinsic values of options outstanding at December 31, 2016 and September 30, 2017 were zero and $5,507, respectively, and the intrinsic value of options vested and unvested expected to vest at September 30, 2017 was $4,951. The total weighted-average grant date fair value of the 229,501 stock options that vested during the nine months ended September 30, 2017 was $5.40. The assumptions used in the Black-Scholes pricing model for stock options granted during the nine months ended September 30, 2017 were as follows: Stock and exercise prices $1.22 – $2.13 Expected dividend yield 0.00% Discount rate-bond equivalent yield 1.79% – 2.08% Expected life (in years) 5.12 – 6.09 Expected volatility 70.0% - 90.0% Using the assumptions described above, with stock and exercise prices being equal on date of grant, the weighted-average estimated fair value of options granted in the nine months ended September 30, 2017 was $1.03 per share. On August 31, 2015, the Company’s Board of Directors approved the issuance of 33,333 performance stock options with an estimated grant date fair value of $4.40 per share and an exercise price of $6.03 per share to its Chief Executive Officer, or CEO, pursuant to the 2013 Plan. On February 29, 2016, the Company’s Board of Directors approved the issuance of 33,333 performance stock options with an estimated grant date fair value of $2.87 per share and an exercise price of $4.02 per share to its CEO pursuant to the 2013 Plan. Vesting of these stock options was based on the Company’s achievement of specified objectives by December 31, 2016 as determined by the Company’s Board of Directors or the Compensation Committee of the Board of Directors. During the nine months ended September 30, 2017, 6,333 of the performance stock options granted on August 31, 2015 and 10,000 of the performance stock options granted on February 29, 2016 were declared vested by the Company’s Board of Directors, and the remaining 50,333 shares underlying these awards were forfeited. On July 25, 2016, the Company entered into an employment agreement with its new Chief Financial Officer, Senior Vice President of Operations and Secretary, or CFO. Pursuant to the terms of this employment agreement, on July 29, 2016 the CFO was granted inducement stock option awards with an exercise price of $1.95 per share to purchase up to (i) 66,666 shares of the Company’s common stock with an estimated grant date fair value of $1.45 per share, 25% of which vested on the one-year anniversary of the commencement of the CFO’s employment with the Company, and remainder of which vest in equal monthly amounts over the following three years, and (ii) 33,333 shares of the Company’s common stock with an estimated grant date fair value of $1.26 per share, which vested upon the Company’s achievement of specified corporate goals for 2016 and the consummation of a specified financing transaction. During the nine months ended September 30, 2017, 16,383 shares of the performance option award granted on July 29, 2016 were declared vested by the Company’s Board of Directors, and the remaining 16,950 shares underlying this award were forfeited. On May 2, 2017, the Company’s Board of Directors approved the issuance of an aggregate of 550,000 performance stock options to be granted on May 31, 2017 to certain of the Company’s employees and all of its executive officers pursuant to the 2013 Plan, of which 200,000 performance stock options were granted to the Company’s CEO, 100,000 performance stock options were granted to its CFO, and 75,000 performance stock options were granted to each of its Chief Scientific Officer, Senior Vice President and Senior Medical Director, Senior Vice President. Each performance stock option granted on May 31, 2017 has an exercise price of $1.50 per share, an estimated grant date fair value of $0.99 per share, and is subject to vesting as determined by the Company’s Board of Directors based on the achievement of specified corporate goals for 2017, provided that none shall vest unless a minimum level of 70% of the Company’s corporate goals for 2017 are achieved, as follows: Percentage of Overall Performance Stock Option Grant Subject to Vesting Target Minimum revenue 20% Cost of revenue reductions and improvements 15% Increase cash generated from operations 15% Minimum cash on-hand at December 31, 2017 15% Minimum customer agreements, product licensing and product launch 20% Implementation of new products and utility trials 15% Total 100% Restricted Stock A summary of RSU activity for the nine months ended September 30, 2017 is as follows: Weighted Number of Average Grant Shares Date Fair Value Outstanding at December 31, 2016 174,249 $ 2.68 Granted 350,000 $ 1.50 Vested and issued (155,829 ) $ 1.96 Forfeited (7,500 ) $ 2.12 Outstanding at September 30, 2017 360,920 $ 1.87 Vested and unvested expected to vest at September 30, 2017 301,420 $ 1.95 At September 30, 2017, the intrinsic values of RSUs outstanding and RSUs unvested and expected to vest were $443,932 and $370,747, respectively. Of the 360,920 RSUs outstanding at September 30, 2017, 10,920 are fully vested. On July 6, 2016, the Compensation Committee of the Company’s Board of Directors approved retention RSUs for an aggregate of 58,332 shares of common stock to three of the Company’s executive officers pursuant to the 2013 Plan, including retention RSUs for 25,000 shares of common stock to its CEO. Each of these retention RSUs has a grant date fair value of $1.86 per share for a grant date fair value of $108,498 to all three officers, in aggregate. These retention RSUs vested fully on the one-year anniversary of the date of grant, and were subject to continuing service by the holders of such RSUs. Pursuant to the terms of the Company’s employment agreement with its CFO dated July 25, 2016, the CFO was granted an inducement RSU award on July 29, 2016 covering 25,000 shares of the Company’s common stock with a grant date fair value of $1.95 per share, 100% of which vested on the one-year anniversary of the commencement of the CFO’s employment with the Company. On May 2, 2017, the Company’s Board of Directors approved the issuance of an aggregate of 175,000 time-based RSUs and 175,000 performance RSUs to be granted on May 31, 2017 to certain of the Company’s employees and all of its executive officers pursuant to the 2013 Plan, of which 50,000 time-based RSUs and 25,000 performance RSUs were granted to its CEO, and 25,000 time-based RSUs and 25,000 performance RSUs were granted to each other executive officer. Each RSU granted on May 31, 2017 has a grant date fair value of $1.50 per share. Vesting of the time-based RSUs granted on May 31, 2017 is subject to continuing service and occurs on the one year anniversary of the vesting commencement date, or May 2, 2018, while the performance RSUs are subject to continuous service and vesting is as determined by the Company’s Board of Directors based on the achievement of specified corporate goals for 2017, provided that none shall vest unless a minimum level of 70% of the Company’s corporate goals for 2017 are achieved, as follows: Percentage of Overall Performance RSU Grant Subject to Vesting Target Minimum revenue 20% Cost of revenue reductions and improvements 15% Increase cash generated from operations 15% Minimum cash on-hand at December 31, 2017 15% Minimum customer agreements, product licensing and product launch 20% Implementation of new products and utility trials 15% Total 100% Stock-based Compensation Expense The following table presents the effects of stock-based compensation related to equity awards to employees and nonemployees on the unaudited condensed statements of operations and comprehensive loss during the periods presented: For the three months ended For the nine months ended September 30, September 30, 2016 2017 2016 2017 Stock Options Cost of revenues $ 34,119 $ 59,720 $ 89,606 $ 133,105 Research and development expenses 28,189 53,405 87,153 121,834 General and administrative expenses 292,381 178,671 829,516 528,406 Sales and marketing expenses 51,924 40,181 91,164 100,327 Total expenses related to stock options 406,613 331,977 1,097,439 883,672 RSUs Cost of revenues 14,918 20,417 16,834 58,717 Research and development expenses 14,131 20,418 15,583 57,490 General and administrative expenses 6,668 74,521 7,676 160,927 Sales and marketing expenses 22,939 28,355 27,447 71,343 Total stock-based compensation $ 465,269 $ 475,688 $ 1,164,979 $ 1,232,149 Stock-based compensation expense was recorded net of estimated forfeitures of 0% - 8% per annum during the nine months ended September 30, 2016 and 2017. As of September 30, 2017, total unrecognized stock-based compensation expense related to unvested stock options and RSUs, adjusted for estimated forfeitures, was approximately $2,128,000 and is expected to be recognized over a weighted-average period of approximately 2.3 years.

Common Stock Warrants Outstandi

Common Stock Warrants Outstanding	9 Months Ended
	Sep. 30, 2017
Other Liabilities Disclosure [Abstract]
Common Stock Warrants Outstanding	9. Common Stock Warrants Outstanding A summary of equity-classified common stock warrant activity for the nine months ended September 30, 2017 is as follows: Average Weighted Remaining Number of Average Exercise Contractual Shares Price Per Share Term in Years Outstanding at December 31, 2016 11,623,957 $ 1.93 4.6 Issued 3,594,639 $ 2.10 Exercised (6,816,850 ) $ 1.10 Expired — — Outstanding at September 30, 2017 8,401,746 $ 2.68 4.2 All warrants outstanding at September 30, 2017 are exercisable, except for the 2,160,000 warrants issued on March 31, 2017, which first became exercisable for a five-year period commencing on October 1, 2017. The intrinsic value of equity-classified common stock warrants outstanding at September 30, 2017 was $378,337.

Net Loss per Common Share

Net Loss per Common Share	9 Months Ended
	Sep. 30, 2017
Earnings Per Share [Abstract]
Net Loss per Common Share	10. Net Loss per Common Share Basic and diluted net loss per common share is determined by dividing net loss applicable to common shareholders by the weighted-average common shares outstanding during the period. Because there is a net loss attributable to common shareholders for the three and-nine months ended September 30, 2016 and 2017, the outstanding RSUs, warrants, and common stock options have been excluded from the calculation of diluted loss per common share because their effect would be anti-dilutive. Therefore, the weighted-average shares used to calculate both basic and diluted loss per share are the same. On September 29, 2016, the Company effected a one-for-three reverse stock split of all common shares outstanding. The calculation of weighted-average shares outstanding has been adjusted for this reverse stock split as if it had occurred on December 31, 2015. The following potentially dilutive securities have been excluded from the computations of diluted weighted-average shares outstanding for the periods presented, as they would be anti-dilutive: For the three and nine-months ended September 30, 2016 2017 Preferred warrants outstanding (number of common stock equivalents) 529 529 Common warrants outstanding 1,896,826 8,401,746 RSUs outstanding 176,749 360,920 Common options outstanding 926,608 2,484,286 Total anti-dilutive common share equivalents 3,000,712 11,247,481

Commitments and Contingencies

Commitments and Contingencies	9 Months Ended
	Sep. 30, 2017
Commitments And Contingencies Disclosure [Abstract]
Commitments and Contingencies	11. Commitments and Contingencies In the normal course of business, the Company may be involved in legal proceedings or threatened legal proceedings. The Company is not party to any legal proceedings or aware of any threatened legal proceedings that are expected to have a material adverse effect on its financial condition, results of operations or liquidity. In February 2016, the Company signed a firm, non-cancelable, and unconditional commitment in an aggregate amount of $1,062,500 with a vendor to purchase certain inventory items, payable in minimum quarterly amounts of $62,500 through May 2020. At September 30, 2017, a balance of $625,000 remained outstanding under this purchase commitment. Payments totaling $328,117 for future sales tax and maintenance obligations associated with financed equipment were outstanding at September 30, 2017, which are expensed as incurred (see Note 7). On September 15, 2017, and as amended on October 17, 2017, the Company executed an equipment financing commitment with a third-party lender for total proceeds to the Company of $150,848, under which the financing commitment was funded by the lender on November 2, 2017 (see Note 7).

Related Party Transactions

Related Party Transactions	9 Months Ended
	Sep. 30, 2017
Related Party Transactions [Abstract]
Related Party Transactions	12. Related Party Transactions A member of the Company’s management is the controlling person of Aegea Biotechnologies, Inc., or Aegea. On September 2, 2012, the Company entered into an Assignment and Exclusive Cross-License Agreement, or the Cross-License Agreement, with Aegea. The Company received payments totaling $19,047 and $15,325 during the year ended December 31, 2016 and the nine months ended September 30, 2017, respectively, from Aegea as reimbursements for shared patent costs under the Cross-License Agreement. Pursuant to a sublease agreement dated March 30, 2015, the Company subleased 9,849 square feet, plus free use of an additional area, of its San Diego facility to an entity affiliated with the Company’s non-executive Chairman for $12,804 per month, with a refundable security deposit of $12,804 received from the subtenant. The initial term of the sublease expired on July 31, 2015, and was subject to renewal on a month-to-month basis thereafter. On February 1, 2017, the Company received notice from the subtenant terminating the sublease effective March 31, 2017. During the three months ended September 30, 2017, the total amount of the $12,804 security deposit previously received from the subtenant was applied against approximately $16,000 in additional rents owed as a result of the subtenant continuing to occupy the subleased areas beyond March 31, 2017, and the balance of approximately $3,200 due to the Company was waived. A total of $115,236 and $51,216 in rental income was recorded to other income/(expense) in the Company’s unaudited condensed statements of operations and comprehensive loss during the nine months ended September 30, 2016 and 2017, respectively. Three members of the Company’s Board of Directors participated in its public offering in May 2016, purchasing an aggregate of 58,335 shares of the Company’s common stock and warrants to purchase up to an aggregate of 40,832 shares of its common stock for total gross proceeds to the Company of $175,000. Additionally, a trust affiliated with Claire K.T. Reiss, who at the time was the beneficial owner of more than 10% of the Company’s outstanding common stock, participated in the Company’s public offering in May 2016, purchasing 204,758 shares of its common stock and warrants to purchase up to 143,330 shares of its common stock for total gross proceeds to the Company of $614,273. Seven members of the Company’s Board of Directors, including its CEO, and all three of the Company’s other executive officers participated in the Company’s public offering in October 2016, purchasing an aggregate of 534,088 shares of common stock and warrants to purchase up to an aggregate of 534,088 shares of common stock for total gross proceeds to the Company of $587,497. Additionally, a trust affiliated with Claire K.T. Reiss, who at the time was the beneficial owner of more than 10% of the Company’s outstanding common stock, participated in the Company’s public offering in October 2016, purchasing 227,272 shares of its common stock and warrants to purchase up 227,272 shares of its common stock for total gross proceeds to the Company of $249,999. Further, several of the Company’s employees and one of its consultants participated in the Company’s public offering in October 2016, purchasing an aggregate of 79,090 shares of its common stock and warrants to purchase up to an aggregate of 79,090 shares of its common stock for total aggregate gross proceeds to the Company of $86,999.

Subsequent Events

Subsequent Events	9 Months Ended
	Sep. 30, 2017
Subsequent Events [Abstract]
Subsequent Events	13. Subsequent Events On September 15, 2017, and as amended on October 17, 2017, the Company executed an equipment financing commitment with a third-party lender for total proceeds to the Company of $150,848, which was funded by the lender on November 2, 2017 (see Note 7).

The Company, Business Activit20

The Company, Business Activities and Basis of Presentation (Policies)	9 Months Ended
	Sep. 30, 2017
Accounting Policies [Abstract]
The Company and Business Activities	The Company and Business Activities The Company was founded in California in May 1997 and is an early stage molecular oncology diagnostics company that develops and commercializes proprietary circulating tumor cell, or CTC, and circulating tumor DNA, or ctDNA, assays utilizing a standard blood sample, or liquid biopsy. The Company’s current and planned assays are intended to provide information to aid healthcare providers to identify specific oncogenic alterations that may qualify a subset of cancer patients for targeted therapy at diagnosis, progression or for monitoring in order to identify specific resistance mechanisms. Often, traditional methodologies such as tissue biopsies are insufficient or unavailable to provide the molecular subtype information necessary for clinical decisions. The Company’s assays have the potential to provide more contemporaneous information on the characteristics of a patient’s disease compared with traditional methodologies such as tissue biopsy and radiographic imaging. Additionally, commencing in October 2017, the Company’s pathology program initiative provides the unique ability for pathologists to participate in the interpretation of liquid biopsy results, and is available to pathology practices and hospital systems throughout the United States. Further, the Company’s proprietary blood collection tubes, which allow for the intact transport of research use only liquid biopsy samples from regions around the world, are anticipated to be sold to laboratory supply distributor(s) commencing in 2018. The Company operates a clinical laboratory that is CLIA-certified (under the Clinical Laboratory Improvement Amendment of 1988) and CAP-accredited (by the College of American Pathologists), and manufactures cell enrichment and extraction microfluidic channels, related equipment and certain reagents to perform the Company’s diagnostic assays in a facility located in San Diego, California. CLIA certification and accreditation are required before any clinical laboratory may perform testing on human specimens for the purpose of obtaining information for the diagnosis, prevention, treatment of disease, or assessment of health. The assays the Company offers are classified as laboratory developed tests under the CLIA regulations. In July 2013, the Company effected a reincorporation to Delaware by merging itself with and into Biocept, Inc., a Delaware corporation, which had been formed to be and was a wholly-owned subsidiary of the Company since July 23, 2013.
Basis of Presentation	Basis of Presentation The financial statements and accompanying notes are prepared in accordance with accounting principles generally accepted in the United States of America. The unaudited condensed financial statements included in this Form 10-Q have been prepared in accordance with the U.S. Securities and Exchange Commission, or SEC, instructions for Quarterly Reports on Form 10-Q. Accordingly, the condensed financial statements are unaudited and do not contain all the information required by U.S. Generally Accepted Accounting Principles, or GAAP, to be included in a full set of financial statements. The balance sheet at December 31, 2016 has been derived from the audited financial statements at that date but does not include all of the information and footnotes required by GAAP for a complete set of financial statements. The audited financial statements for the year ended December 31, 2016, filed with the U.S. Securities and Exchange Commission, or SEC, with our Annual Report on Form 10-K on March 28, 2017 include a summary of our significant accounting policies and should be read in conjunction with this Form 10-Q. In the opinion of management, all material adjustments necessary to present fairly the results of operations for such periods have been included in this Form 10-Q. All such adjustments are of a normal recurring nature. The results of operations for interim periods are not necessarily indicative of the results of operations for the entire year. Certain prior period balances have been reclassified to conform to the current period presentation.
Reverse Stock Split	Reverse Stock Split On September 27, 2016, the Company’s stockholders approved, and the Company filed, an amendment to the Company’s amended and restated certificate of incorporation to effect a one-for-three reverse stock split of the Company’s outstanding common stock, and to increase the authorized number of shares of the Company’s common stock from 40,000,000 to 150,000,000 shares. The one-for-three reverse stock split was effected September 29, 2016
Revenue Recognition and Related Reserves	Revenue Recognition and Related Reserves The Company's commercial revenues are generated from diagnostic services provided to physicians and billed to third-party insurance payers such as managed care organizations, Medicare and Medicaid and patients for any deductibles, coinsurance or copayments that may be due. The Company recognizes revenue in accordance with the provision of ASC 954-605, Health Care Entities—Revenue Recognition, which requires that four basic criteria must be met prior to recognition of revenue: (1) persuasive evidence of an arrangement exists; (2) delivery has occurred and title and the risks and rewards of ownership have been transferred to the client or services have been rendered; (3) the price is fixed or determinable; and (4) collectability is reasonably assured. Commencing on March 31, 2017, the Company recognizes commercial revenue related to billings for assays delivered and billed to Medicare and other third-party payers on an accrual basis when amounts that will ultimately be realized can be estimated upon delivery, whereby prior to March 31, 2017, the Company recognized revenues for its commercial diagnostic services on a cash basis as collected because the amounts ultimately expected to be received could not be estimated upon delivery due to insufficient collection history experience. The Company bills third-party payers on a fee-for-service basis at the Company’s list price and third-party commercial revenue is recorded net of contractual discounts, payer-specific allowances and other reserves. The Company’s development services revenues are supported by contractual agreements and generated from assay development services provided to entities, as well as certain other diagnostic services provided to physicians. Diagnostic services are completed upon the delivery of assay results to the prescribing physician, at which time the Company bills for the service. The Company’s gross commercial revenues billed are subject to estimated deductions for such contractual discounts, payer-specific allowances and other reserves to arrive at reported net revenues, which relate to differences between amounts billed and corresponding amounts estimated to be subsequently collected. These third-party payer discounts and sales allowances are estimated based on a number of assumptions and factors, including historical payment trends, seasonality associated with the annual reset of patient deductible limits on January 1 of each year, and current and estimated future payments. Specifically, the Company maintains four such reserves: the reserve for contractual discounts, the reserve for aged non-patient receivables, the reserve for estimated patient receivables, and the reserve for other payer-specific sales allowances. The reserve for contractual discounts relates to discounts to gross amounts billed to Medicare and contracted third-party payers to arrive at the deemed “allowed expense" amount covered by that payer. The Company’s contracted third-party commercial sales are recorded using an actual or contracted fee schedule at the time of sale, while estimated fee schedules are maintained for each non-contracted payer separately as part of other payer-specific sales allowances. Contractual discounts are recorded at the transaction level at the time of sale based on a fee schedule that is maintained for each contracted third-party payer. The Company periodically adjusts fee schedules for both contracted and non-contracted third-party payers based upon historical payment trends. The reserve for aged non-patient receivables reduces gross amounts billed to non-contracted third-party payers for amounts estimated to be collected according to the age of the outstanding balance. The reserve for estimated patient receivables reduces gross amounts billed to third-party payers for amounts estimated to be collected directly from individual patients, such as copayments, deductibles, or amounts otherwise designated as patient responsibility. The reserve for other payer-specific sales allowances relates to the amounts billed to non-contracted third-party payers that are estimated to not be covered by that specific payer’s coverage policies, as well as estimated necessary adjustments to gross amounts billed based on historical collection experience for a particular third-party payer unrelated to the age of outstanding balances. The estimates of amounts that will ultimately be realized from commercial diagnostic services require significant judgment by management. Patients do not enter into direct agreements with the Company that commit them to pay any portion of the cost of the tests in the event that they have not met their annual deductible limit under their insurance policy, if any, or if their insurance otherwise declines to reimburse the Company. Adjustments to the estimated payment amounts are recorded at the time of final collection and settlement of each transaction as an adjustment to commercial revenue. The estimation process used to determine third-party payer discounts and sales allowance has been applied on a consistent basis since March 31, 2017, and no significant subsequent adjustments have been necessary to increase or decrease these discounts and allowances as a result of changes in underlying estimates. The composition of the Company’s gross and net revenues recognized during the three and nine-months ended September 30, 2016 and 2017 is as follows: For the three months ended September 30, For the nine months ended September 30, 2016 2017 2016 2017 Commercial revenues recognized upon delivery $ - $ 3,602,194 $ - $ 12,298,790 Development services revenues recognized upon delivery 71,723 67,394 170,052 211,736 Commercial revenues recognized upon cash collection 975,557 102,234 1,761,457 1,158,277 Total gross revenues 1,047,280 3,771,822 1,931,509 13,668,803 Provisions for contractual discounts — (1,729,805 ) — (4,545,128 ) Provisions for aged non-patient receivables — (152,889 ) — (598,532 ) Provisions for estimated patient receivables — 27,909 — (90,931 ) Provisions for other payer-specific sales allowances — (805,626 ) — (4,360,775 ) Net revenues $ 1,047,280 $ 1,111,411 $ 1,931,509 $ 4,073,437 During the nine months ended September 30, 2017, the Company recorded $839,431 in nonrecurring net revenue as a result of recognizing revenue on an accrual basis commencing on March 31, 2017 associated with cases delivered on or prior to December 31, 2016, representing a corresponding decrease in net loss per common share of $0.03. The incremental net revenue as a result of recognizing revenue on an accrual basis commencing on March 31, 2017, or the total amount of net revenue recorded in excess of the amount of commercial cash collections, was $125,007 and $1,041,890 during the three and nine-months ended September 30, 2017, respectively, representing corresponding decreases in net loss per common share of zero and $0.04, respectively. A summary of activity in the Company’s gross and net accounts receivable balances, as well as corresponding reserves, during the nine months ended September 30, 2017 is as follows: Balance at Amounts Settlements Balance at December 31, Recognized Upon September 30, 2016 Upon Delivery Adjudication 2017 Accounts receivable, gross $ 128,969 $ 12,510,526 $ (5,649,054 ) $ 6,990,441 Reserve for contractual discounts — (4,545,128 ) 2,399,458 (2,145,670 ) Reserve for aged non-patient receivables — (598,532 ) 70,950 (527,582 ) Reserve for estimated patient receivables — (90,931 ) 1,072 (89,859 ) Reserve for other payer-specific sales allowances — (4,360,775 ) 1,266,817 (3,093,958 ) Accounts receivable, net $ 128,969 $ 2,915,160 $ (1,910,757 ) $ 1,133,372
Concentration of Risk	Concentration of Risk Concentrations of credit risk with respect to revenues are primarily limited to geographies to which the Company provides a significant volume of its services, and to specific third-party payers of the Company’s services such as Medicare, insurance companies, and other third-party payers. The Company’s client base consists of a large number of geographically dispersed clients diversified across various customer types. The Company's third-party payers that represent more than 10% of total net revenues in any period presented, and their related net revenue amount as a percentage of total net revenues, during the three and nine-months ended September 30, 2016 and 2017 were as follows: For the three months ended September 30, For the nine months ended September 30, 2016 2017 2016 2017 Medicare and Medicare Advantage 63 % 45 % 54 % 41 % Blue Cross Blue Shield 15 % 16 % 12 % 17 % United Healthcare 19 % 14 % 19 % 12 % The Company's third-party payers that represent more than 10% of total net accounts receivable, and their related net accounts receivable balance as a percentage of total net accounts receivable, at September 30, 2017 were as follows: Blue Cross Blue Shield 27 % Medicare and Medicare Advantage 20 % United Healthcare 14 %
Recent Accounting Pronouncements	Recent Accounting Pronouncements In May 2014, and as subsequently updated and amended from time to time, the Financial Accounting Standards Board, or the FASB, issued authoritative guidance that requires entities to recognize revenue when it transfers promised goods or services to customers in an amount that reflects the consideration to which the entity expects to be entitled to in exchange for those goods or services. This proposed guidance has been deferred and would be effective for annual reporting periods beginning after December 15, 2017, including interim periods within that reporting period, and may be applied retrospectively to each prior period presented or retrospectively with the cumulative effect recognized as of the date of adoption. Earlier application is permitted only as of annual reporting periods beginning after December 15, 2016, including interim periods within that reporting period. As the Company has not yet completed its final review of the impact of the new guidance but expects to during 2017, the Company has not determined whether the adoption of this guidance will have a material impact on its financial statements or disclosures. The Company is still evaluating disclosure requirements under the new guidance, and will continue to evaluate additional changes, modifications or interpretations to the guidance which may impact the current conclusions. The Company expects to adopt the new standard for the fiscal year beginning January 1, 2018 and anticipates that the modified retrospective application method will be applied. In July 2015, the FASB issued authoritative guidance requiring entities that do not measure inventory using the retail inventory method or on a last-in, first-out basis to record inventory at the lower of cost and net realizable value. Net realizable value is the estimated selling prices in the ordinary course of business, less reasonably predictable costs of completion, disposal, and transportation. This guidance is effective on a prospective basis for fiscal years beginning after December 15, 2016, including interim periods within those fiscal years. Early adoption is permitted. The Company adopted this guidance for the reporting period beginning January 1, 2017. The adoption of this guidance did not have a material impact on the Company’s financial statements or disclosures. In January 2016, the FASB issued authoritative guidance requiring, among other things, that certain equity investments be measured at fair value with changes in fair value recognized in net income, that financial assets and financial liabilities be presented separately by measurement category and form of financial asset on the balance sheet or the accompanying notes to the financial statements, that the prior requirement to disclose the method(s) and significant assumptions used to estimate the fair value that is required to be disclosed for financial instruments measured at amortized cost on the balance sheet be eliminated, and that a reporting organization is to present separately in other comprehensive income the portion of the total change in the fair value of a liability resulting from a change in the instrument-specific credit risk when the organization has elected to measure the liability at fair value in accordance with the fair value option for financial instruments. This guidance is effective for fiscal years, and interim periods within those years, beginning after December 15, 2017. Early adoption of the instrument-specific credit risk amendment is permitted. The Company expects to adopt this guidance for the fiscal year beginning on January 1, 2018, and does not anticipate that the adoption of this guidance will have a material impact on its financial statements or disclosures because the Company does not currently have any equity method investments. In February 2016, the FASB issued authoritative guidance requiring, among other things, that entities recognize the assets and liabilities arising from leases on the balance sheet under revised criteria, while the classification criteria for distinguishing between finance leases and operating leases are substantially similar to the classification criteria in the previous leases guidance. In transition, lessees and lessors are required to recognize and measure leases at the beginning of the earliest period presented using a modified retrospective approach. This guidance is effective for fiscal years beginning after December 15, 2018, including interim periods within those fiscal years. Early adoption is permitted. The Company anticipates that the adoption of this guidance will materially affect its statement of financial position and will require changes to its processes. The Company expects to adopt this guidance for the reporting period beginning on January 1, 2019, and has not yet made any decision on the method of adoption with respect to the optional practical expedients, but expects to during 2018. In March 2016, the FASB issued authoritative guidance clarifying that a change in the counterparty to a derivative instrument that has been designated as the hedging instrument does not necessarily require de-designation of that hedging relationship, provided that all other applicable hedge accounting criteria continue to be met. This guidance is effective on either a prospective basis or modified retrospective basis for fiscal years beginning after December 15, 2016, and interim periods within those fiscal years. Early adoption is permitted. The Company adopted this guidance for the reporting period beginning January 1, 2017. The adoption of this guidance did not have a material impact on the Company’s financial statements or disclosures. In March 2016, the FASB issued authoritative guidance requiring entities to assess whether contingent call (put) options that can accelerate the payment of principal on debt instruments are clearly and closely related to their debt hosts, and clarifies what steps are required when assessing whether the economic characteristics and risks of call (put) options are clearly and closely related to the economic characteristics and risks of their debt hosts. This guidance is effective on a modified retrospective basis for fiscal years beginning after December 15, 2016, and interim periods within those fiscal years. Early adoption is permitted. The Company adopted this guidance for the reporting period beginning January 1, 2017. The adoption of this guidance did not have a material impact on the Company’s financial statements or disclosures. In March 2016, the FASB issued authoritative guidance simplifying the accounting for stock compensation. This guidance, among other things, amends existing accounting and classification requirements primarily around income taxes, forfeitures, and cash payments associated with share-based payment awards to employees. This guidance is effective for fiscal years beginning after December 15, 2016, including interim periods within those fiscal years. Early adoption is permitted. The Company adopted this guidance for the reporting period beginning January 1, 2017. The adoption of this guidance did not have a material impact on the Company’s financial statements or disclosures. In August 2016, the FASB issued authoritative guidance clarifying the classification of certain cash receipts and cash payments in the statement of cash flows. This guidance is effective for fiscal years beginning after December 15, 2017, including interim periods within those fiscal years, on a retrospective transition method to each period presented. Early adoption is permitted. The Company currently intends to adopt this guidance for the fiscal year beginning on January 1, 2018, and does not anticipate that the adoption of this guidance will have a material impact on its financial statements or disclosures because the Company has not historically engaged in the transactions encompassed by the proposed guidance. In January 2017, the FASB issued authoritative guidance clarifying the definition of a business when evaluating transactions involving acquisitions or disposals of assets or businesses. This guidance is effective for fiscal years beginning after December 15, 2017, including interim periods within those fiscal years. Certain applications of this guidance are permitted for early adoption. The Company currently intends to adopt this guidance for the fiscal year beginning on January 1, 2018, and does not anticipate that the adoption of this guidance will have a material impact on its financial statements or disclosures because the Company has not historically acquired or disposed of material assets or businesses. In January 2017, the FASB issued authoritative guidance eliminating the “Step 2” requirement for an entity to determine the fair value of its assets and liabilities for goodwill impairment testing in the same manner that would be required for those assumed in a business combination. Instead, the amended guidance allows an entity to perform goodwill impairment testing by comparing the fair value of a reporting unit with its carrying amount. This guidance is effective for any goodwill impairment tests in fiscal years beginning after December 15, 2019, including interim periods within those fiscal years. Early adoption is permitted. The Company currently intends to adopt this guidance for the fiscal year beginning January 1, 2020, and does not anticipate that the adoption of this guidance will have a material impact on its financial statements or disclosures because the Company does not currently have any recorded goodwill. In February 2017, the FASB issued authoritative guidance clarifying the definition of the term “in substance nonfinancial asset” when accounting for transfers of financial and nonfinancial assets, and other matters concerning the transfer, sale and partial sale of nonfinancial assets to both consolidated entities and non-consolidated counterparties. This guidance is effective for fiscal years beginning after December 15, 2017, including interim periods within that reporting period. Early adoption is permitted. The Company currently intends to adopt this guidance for the fiscal year beginning on January 1, 2018, and does not anticipate that the adoption of this guidance will have a material impact on its financial statements or disclosures because the Company has not historically engaged in transfers, sales or partial sales of nonfinancial assets. In March 2017, the FASB issued authoritative guidance shortening the amortization period to the earliest call date for certain purchased callable debt securities held at a premium. This guidance is effective for fiscal years beginning after December 15, 2018, including interim periods within those fiscal years. Early adoption is permitted. The Company currently intends to adopt this guidance for the fiscal year beginning on January 1, 2019, and does not anticipate that the adoption of this guidance will have a material impact on its financial statements or disclosures because the Company does not currently hold any callable debt securities. In May 2017, the FASB issued authoritative guidance clarifying what modifications to a share-based payment award may be considered substantive, and therefore requiring the application of modification accounting. This guidance is effective for fiscal years beginning after December 15, 2017, including interim periods within those fiscal years. Early adoption is permitted. The Company currently intends to adopt this guidance for the fiscal year beginning on January 1, 2018, and does not anticipate that the adoption of this guidance will have a material impact on its financial statements or disclosures because the Company does not currently expect any significant modifications to outstanding share-based payment awards. In July 2017, the FASB issued authoritative guidance changing the classification analysis of certain equity-linked financial instruments (or embedded features) with down round features, whereby a down round feature no longer precludes equity classification when assessing whether the instrument is indexed to an entity’s own stock, and also clarifying existing disclosure requirements for equity-classified instruments. This guidance is effective for fiscal years beginning after December 15, 2019, and interim periods within fiscal years beginning after December 15, 2020. Early adoption is permitted. The Company currently intends to adopt this guidance for the fiscal year beginning on January 1, 2020, and does not anticipate that the adoption of this guidance will have a material impact on its financial statements or disclosures because the Company does not currently hold any significant financial instruments with down round features. In August 2017, the FASB issued authoritative guidance that expands and refines hedge accounting for both nonfinancial and financial risk components and align the recognition and presentation of the effects of the hedging instrument and the hedged item in the financial statements. This guidance is effective for fiscal years beginning after December 15, 2018, and interim periods within those fiscal years. Early application is permitted. The Company currently intends to adopt this guidance for the fiscal year beginning on January 1, 2019, and does not anticipate that the adoption of this guidance will have a material impact on its financial statements or disclosures because the Company does not currently hold any financial instruments accounted for as a hedging activity.

The Company, Business Activit21

The Company, Business Activities and Basis of Presentation (Tables)	9 Months Ended
	Sep. 30, 2017
Accounting Policies [Abstract]
Composition of Gross and Net Revenues Recognized	The composition of the Company’s gross and net revenues recognized during the three and nine-months ended September 30, 2016 and 2017 is as follows: For the three months ended September 30, For the nine months ended September 30, 2016 2017 2016 2017 Commercial revenues recognized upon delivery $ - $ 3,602,194 $ - $ 12,298,790 Development services revenues recognized upon delivery 71,723 67,394 170,052 211,736 Commercial revenues recognized upon cash collection 975,557 102,234 1,761,457 1,158,277 Total gross revenues 1,047,280 3,771,822 1,931,509 13,668,803 Provisions for contractual discounts — (1,729,805 ) — (4,545,128 ) Provisions for aged non-patient receivables — (152,889 ) — (598,532 ) Provisions for estimated patient receivables — 27,909 — (90,931 ) Provisions for other payer-specific sales allowances — (805,626 ) — (4,360,775 ) Net revenues $ 1,047,280 $ 1,111,411 $ 1,931,509 $ 4,073,437
Summary of Activity in Gross and Net Accounts Receivable Balances and Reserves	A summary of activity in the Company’s gross and net accounts receivable balances, as well as corresponding reserves, during the nine months ended September 30, 2017 is as follows: Balance at Amounts Settlements Balance at December 31, Recognized Upon September 30, 2016 Upon Delivery Adjudication 2017 Accounts receivable, gross $ 128,969 $ 12,510,526 $ (5,649,054 ) $ 6,990,441 Reserve for contractual discounts — (4,545,128 ) 2,399,458 (2,145,670 ) Reserve for aged non-patient receivables — (598,532 ) 70,950 (527,582 ) Reserve for estimated patient receivables — (90,931 ) 1,072 (89,859 ) Reserve for other payer-specific sales allowances — (4,360,775 ) 1,266,817 (3,093,958 ) Accounts receivable, net $ 128,969 $ 2,915,160 $ (1,910,757 ) $ 1,133,372
Summary of Third-Party Payers That Represent More Than 10% of Total Net Revenues and Total Net Accounts Receivable and Their Related Percentage	The Company's third-party payers that represent more than 10% of total net revenues in any period presented, and their related net revenue amount as a percentage of total net revenues, during the three and nine-months ended September 30, 2016 and 2017 were as follows: For the three months ended September 30, For the nine months ended September 30, 2016 2017 2016 2017 Medicare and Medicare Advantage 63 % 45 % 54 % 41 % Blue Cross Blue Shield 15 % 16 % 12 % 17 % United Healthcare 19 % 14 % 19 % 12 % The Company's third-party payers that represent more than 10% of total net accounts receivable, and their related net accounts receivable balance as a percentage of total net accounts receivable, at September 30, 2017 were as follows: Blue Cross Blue Shield 27 % Medicare and Medicare Advantage 20 % United Healthcare 14 %

Fair Value Measurement (Tables)

Fair Value Measurement (Tables)	9 Months Ended
	Sep. 30, 2017
Fair Value Disclosures [Abstract]
Assumptions Used for Determining Fair Values of Common Stock Warrants	As of the closing of the Company’s March 31, 2017 offering, the estimated grant date fair value of $1.31 per share associated with the warrants to purchase up to 2,160,000 shares of common stock issued in this offering, or a total of approximately $2.8 million, was recorded as an offset to additional paid-in capital, and was estimated using a Black-Scholes valuation model with the following assumptions: Stock price $ 2.13 Exercise price $ 2.50 Expected dividend yield 0.00 % Discount rate-bond equivalent yield 1.93 % Expected life (in years) 5.00 Expected volatility 80.0 % As of the closing of the Company’s August 9, 2017 offering, the estimated grant date fair value of $1.03 per share associated with the warrant to purchase up to 1,434,639 shares of common stock issued in this offering, or a total of approximately $1.5 million, was recorded as an offset to additional paid-in capital, and was estimated using a Black-Scholes valuation model with the following assumptions: Stock price $ 1.39 Exercise price $ 1.50 Expected dividend yield 0.00 % Discount rate-bond equivalent yield 1.81 % Expected life (in years) 5.00 Expected volatility 100.0 %

Balance Sheet Details (Tables)

Balance Sheet Details (Tables)	9 Months Ended
	Sep. 30, 2017
Organization Consolidation And Presentation Of Financial Statements [Abstract]
Schedule of Fixed Assets and Accrued Liabilities	The following provides certain balance sheet details: December 31, September 30, 2016 2017 Fixed Assets Machinery and equipment $ 2,728,468 $ 2,938,281 Furniture and office equipment 143,726 147,976 Computer equipment and software 620,582 1,526,482 Leasehold improvements 517,968 550,246 Financed equipment 1,559,690 1,922,418 Construction in process 169,896 7,481 Total fixed assets, gross 5,740,330 7,092,884 Less accumulated depreciation and amortization (3,933,999 ) (4,173,088 ) Total fixed assets, net $ 1,806,331 $ 2,919,796 Accrued Liabilities Accrued interest $ 20,776 $ 324,406 Accrued payroll 168,727 477,889 Accrued vacation 364,953 503,380 Accrued bonuses 422,868 625,682 Accrued sales commissions 77,844 48,390 Current portion of deferred rent 67,085 106,418 Accrued other 37,783 88,220 Total accrued liabilities $ 1,160,036 $ 2,174,385

Equipment Financings (Tables)

Equipment Financings (Tables)	9 Months Ended
	Sep. 30, 2017
Capital Lease Obligations [Abstract]
Schedule of Remaining Future Minimum Lease Payments for Financed Equipment Obligations	The following schedule sets forth the remaining future minimum lease payments outstanding under financed equipment arrangements, as well as corresponding remaining sales tax and maintenance obligation payments that are expensed as incurred, due within each respective fiscal year ending December 31, as well as the present value of the total amount of remaining minimum lease payments, as of September 30, 2017: Maintenance Minimum and Sales Tax Lease Obligation Payments Payments 2017 $ 79,763 $ 8,954 2018 338,273 58,355 2019 313,529 68,925 2020 277,291 54,768 2021 267,665 48,802 Thereafter 522,397 88,313 Total payments 1,798,918 328,117 Less amount representing interest (544,210 ) — Present value of payments $ 1,254,708 $ 328,117

Stock-Based Compensation (Table

Stock-Based Compensation (Tables)	9 Months Ended
	Sep. 30, 2017
Summary of Stock Option Activity	A summary of stock option activity for the nine months ended September 30, 2017 is as follows: Weighted Average Weighted Remaining Number of Average Exercise Contractual Shares Price Per Share Term in Years Outstanding at December 31, 2016 896,662 $ 8.80 8.5 Granted 1,711,196 $ 1.49 Exercised — Cancelled/forfeited/expired (123,572 ) $ 5.13 8.7 Outstanding at September 30, 2017 2,484,286 $ 3.93 8.9 Vested and unvested expected to vest at September 30, 2017 2,267,826 $ 4.16 8.8
Assumptions Used for Determining Fair Value of Stock Options Under Black-Scholes Pricing Model	The assumptions used in the Black-Scholes pricing model for stock options granted during the nine months ended September 30, 2017 were as follows: Stock and exercise prices $1.22 – $2.13 Expected dividend yield 0.00% Discount rate-bond equivalent yield 1.79% – 2.08% Expected life (in years) 5.12 – 6.09 Expected volatility 70.0% - 90.0%
Summary of RSU Activity	A summary of RSU activity for the nine months ended September 30, 2017 is as follows: Weighted Number of Average Grant Shares Date Fair Value Outstanding at December 31, 2016 174,249 $ 2.68 Granted 350,000 $ 1.50 Vested and issued (155,829 ) $ 1.96 Forfeited (7,500 ) $ 2.12 Outstanding at September 30, 2017 360,920 $ 1.87 Vested and unvested expected to vest at September 30, 2017 301,420 $ 1.95
Effects of Stock-Based Compensation Related to Equity Awards to Employees and Nonemployees on Condensed Statement of Operations and Comprehensive Loss	The following table presents the effects of stock-based compensation related to equity awards to employees and nonemployees on the unaudited condensed statements of operations and comprehensive loss during the periods presented: For the three months ended For the nine months ended September 30, September 30, 2016 2017 2016 2017 Stock Options Cost of revenues $ 34,119 $ 59,720 $ 89,606 $ 133,105 Research and development expenses 28,189 53,405 87,153 121,834 General and administrative expenses 292,381 178,671 829,516 528,406 Sales and marketing expenses 51,924 40,181 91,164 100,327 Total expenses related to stock options 406,613 331,977 1,097,439 883,672 RSUs Cost of revenues 14,918 20,417 16,834 58,717 Research and development expenses 14,131 20,418 15,583 57,490 General and administrative expenses 6,668 74,521 7,676 160,927 Sales and marketing expenses 22,939 28,355 27,447 71,343 Total stock-based compensation $ 465,269 $ 475,688 $ 1,164,979 $ 1,232,149
Stock Options [Member]
Schedule of Percentage Of Overall Performance Grant Subject To Vesting	Each performance stock option granted on May 31, 2017 has an exercise price of $1.50 per share, an estimated grant date fair value of $0.99 per share, and is subject to vesting as determined by the Company’s Board of Directors based on the achievement of specified corporate goals for 2017, provided that none shall vest unless a minimum level of 70% of the Company’s corporate goals for 2017 are achieved, as follows: Percentage of Overall Performance Stock Option Grant Subject to Vesting Target Minimum revenue 20% Cost of revenue reductions and improvements 15% Increase cash generated from operations 15% Minimum cash on-hand at December 31, 2017 15% Minimum customer agreements, product licensing and product launch 20% Implementation of new products and utility trials 15% Total 100%
RSUs [Member]
Schedule of Percentage Of Overall Performance Grant Subject To Vesting	Vesting of the time-based RSUs granted on May 31, 2017 is subject to continuing service and occurs on the one year anniversary of the vesting commencement date, or May 2, 2018, while the performance RSUs are subject to continuous service and vesting is as determined by the Company’s Board of Directors based on the achievement of specified corporate goals for 2017, provided that none shall vest unless a minimum level of 70% of the Company’s corporate goals for 2017 are achieved, as follows: Percentage of Overall Performance RSU Grant Subject to Vesting Target Minimum revenue 20% Cost of revenue reductions and improvements 15% Increase cash generated from operations 15% Minimum cash on-hand at December 31, 2017 15% Minimum customer agreements, product licensing and product launch 20% Implementation of new products and utility trials 15% Total 100%

Common Stock Warrants Outstan26

Common Stock Warrants Outstanding (Tables)	9 Months Ended
	Sep. 30, 2017
Equity Classified Warrants [Abstract]
Summary of Equity-Classified Common Stock Warrant Activity	A summary of equity-classified common stock warrant activity for the nine months ended September 30, 2017 is as follows: Average Weighted Remaining Number of Average Exercise Contractual Shares Price Per Share Term in Years Outstanding at December 31, 2016 11,623,957 $ 1.93 4.6 Issued 3,594,639 $ 2.10 Exercised (6,816,850 ) $ 1.10 Expired — — Outstanding at September 30, 2017 8,401,746 $ 2.68 4.2

Net Loss per Common Share (Tabl

Net Loss per Common Share (Tables)	9 Months Ended
	Sep. 30, 2017
Earnings Per Share [Abstract]
Schedule of Anti-Dilutive Securities Excluded from Computations of Diluted Weighted-Average Shares	The following potentially dilutive securities have been excluded from the computations of diluted weighted-average shares outstanding for the periods presented, as they would be anti-dilutive: For the three and nine-months ended September 30, 2016 2017 Preferred warrants outstanding (number of common stock equivalents) 529 529 Common warrants outstanding 1,896,826 8,401,746 RSUs outstanding 176,749 360,920 Common options outstanding 926,608 2,484,286 Total anti-dilutive common share equivalents 3,000,712 11,247,481

The Company, Business Activit28

The Company, Business Activities and Basis of Presentation - Additional Information (Detail)	Sep. 29, 2016	Sep. 30, 2017USD ($)$ / sharesshares	Sep. 30, 2017USD ($)$ / sharesshares	Dec. 31, 2016shares	Sep. 27, 2016shares
The Company, Business Activities and Basis of Presentation [Line Items]
Stockholders equity reverse stock split ratio	0.33
Common stock, shares authorized		150,000,000	150,000,000	150,000,000
Description of reverse stock split			On September 27, 2016, the Company’s stockholders approved, and the Company filed, an amendment to the Company’s amended and restated certificate of incorporation to effect a one-for-three reverse stock split of the Company’s outstanding common stock, and to increase the authorized number of shares of the Company’s common stock from 40,000,000 to 150,000,000 shares. The one-for-three reverse stock split was effected September 29, 2016.
Nonrecurring net revenue recognized on accrual basis associated with cases delivered | $			$ 839,431
Increase (decrease) in net income (loss) per common share on nonrecurring net revenue | $ / shares			$ (0.03)
Net revenue recorded in excess of commercial cash collections | $		$ 125,007	$ 1,041,890
Increase decrease in net income (loss) per common share | $ / shares		$ 0	$ (0.04)
Minimum [Member]
The Company, Business Activities and Basis of Presentation [Line Items]
Common stock, shares authorized					40,000,000
Maximum [Member]
The Company, Business Activities and Basis of Presentation [Line Items]
Common stock, shares authorized					150,000,000

The Company, Business Activit29

The Company, Business Activities and Basis of Presentation - Composition of Gross and Net Revenues Recognized (Detail) - USD ($)	3 Months Ended		9 Months Ended
	Sep. 30, 2017	Sep. 30, 2016	Sep. 30, 2017	Sep. 30, 2016
Revenue Recognition [Abstract]
Commercial revenues recognized upon delivery	$ 3,602,194		$ 12,298,790
Development services revenues recognized upon delivery	67,394	$ 71,723	211,736	$ 170,052
Commercial revenues recognized upon cash collection	102,234	975,557	1,158,277	1,761,457
Total gross revenues	3,771,822	1,047,280	13,668,803	1,931,509
Provisions for contractual discounts	(1,729,805)		(4,545,128)
Provisions for aged non-patient receivables	(152,889)		(598,532)
Provisions for estimated patient receivables	27,909		(90,931)
Provisions for other payer-specific sales allowances	(805,626)		(4,360,775)
Net revenues	$ 1,111,411	$ 1,047,280	$ 4,073,437	$ 1,931,509

The Company, Business Activit30

The Company, Business Activities and Basis of Presentation - Summary of Activity in Gross and Net Accounts Receivable Balances and Reserves (Detail)	9 Months Ended
	Sep. 30, 2017USD ($)
The Company, Business Activities and Basis of Presentation [Line Items]
Gross and net accounts receivable, Beginning Balance	$ 128,969
Amounts Recognized Upon Delivery	2,915,160
Settlements Upon Adjudication	(1,910,757)
Gross and net accounts receivable, Ending Balance	1,133,372
Accounts Receivable Gross [Member]
The Company, Business Activities and Basis of Presentation [Line Items]
Gross and net accounts receivable, Beginning Balance	128,969
Amounts Recognized Upon Delivery	12,510,526
Settlements Upon Adjudication	(5,649,054)
Gross and net accounts receivable, Ending Balance	6,990,441
Reserve for Contractual Discounts [Member]
The Company, Business Activities and Basis of Presentation [Line Items]
Amounts Recognized Upon Delivery	(4,545,128)
Settlements Upon Adjudication	2,399,458
Gross and net accounts receivable, Ending Balance	(2,145,670)
Reserve for Aged Non-patient Receivables [Member]
The Company, Business Activities and Basis of Presentation [Line Items]
Amounts Recognized Upon Delivery	(598,532)
Settlements Upon Adjudication	70,950
Gross and net accounts receivable, Ending Balance	(527,582)
Reserve for Estimated Patient Receivables [Member]
The Company, Business Activities and Basis of Presentation [Line Items]
Amounts Recognized Upon Delivery	(90,931)
Settlements Upon Adjudication	1,072
Gross and net accounts receivable, Ending Balance	(89,859)
Reserve for Other Payer-specific Sales Allowances [Member]
The Company, Business Activities and Basis of Presentation [Line Items]
Amounts Recognized Upon Delivery	(4,360,775)
Settlements Upon Adjudication	1,266,817
Gross and net accounts receivable, Ending Balance	$ (3,093,958)

The Company, Business Activit31

The Company, Business Activities and Basis of Presentation - Summary of Third-Party Payers That Represent More Than 10% of Total Net Revenues and Total Net Accounts Receivable and Their Related Percentage (Detail)	3 Months Ended		9 Months Ended
	Sep. 30, 2017	Sep. 30, 2016	Sep. 30, 2017	Sep. 30, 2016
Customer Concentration Risk [Member] | Net Revenues [Member] | Blue Cross Blue Shield [Member]
Concentration Risk [Line Items]
Concentration risk percentage	16.00%	15.00%	17.00%	12.00%
Customer Concentration Risk [Member] | Net Revenues [Member] | Medicare and Medicare Advantage [Member]
Concentration Risk [Line Items]
Concentration risk percentage	45.00%	63.00%	41.00%	54.00%
Customer Concentration Risk [Member] | Net Revenues [Member] | United Healthcare [Member]
Concentration Risk [Line Items]
Concentration risk percentage	14.00%	19.00%	12.00%	19.00%
Credit Concentration Risk [Member] | Net Accounts Receivable [Member] | Blue Cross Blue Shield [Member]
Concentration Risk [Line Items]
Concentration risk percentage			27.00%
Credit Concentration Risk [Member] | Net Accounts Receivable [Member] | Medicare and Medicare Advantage [Member]
Concentration Risk [Line Items]
Concentration risk percentage			20.00%
Credit Concentration Risk [Member] | Net Accounts Receivable [Member] | United Healthcare [Member]
Concentration Risk [Line Items]
Concentration risk percentage			14.00%

Liquidity and Going Concern U32

Liquidity and Going Concern Uncertainty- Additional Information (Detail) - USD ($)	Aug. 11, 2017	Aug. 09, 2017	Mar. 31, 2017	Oct. 19, 2016	Oct. 14, 2016	May 04, 2016	Feb. 29, 2016	Sep. 30, 2017	Sep. 30, 2016	Sep. 30, 2017	Sep. 30, 2016	Sep. 30, 2017	Dec. 31, 2016	Dec. 31, 2015	May 31, 2015
Liquidity And Managements Plans [Line Items]
Cash								$ 5,879,025	$ 678,855	$ 5,879,025	$ 678,855	$ 5,879,025	$ 4,609,332	$ 8,821,329
Accumulated deficit								(189,583,034)		(189,583,034)		(189,583,034)	(173,635,870)
Net loss								(5,821,306)	$ (4,743,076)	(15,947,164)	$ (14,212,448)		$ (18,400,000)
Aggregate net interest-bearing indebtedness								3,300,000		3,300,000		3,300,000
Due within one year								2,400,000		2,400,000		2,400,000
Other non-interest bearing current liabilities								3,400,000		3,400,000		3,400,000
Unconditional purchase commitment aggregate amount							$ 1,062,500	$ 625,000		$ 625,000		625,000
Unconditional purchase commitment payment terms										Quarterly
Unconditional purchase commitment period										May 31, 2020
Proceeds from issuance of common stock, net of issuance costs		$ 2,000,000
Proceeds from exercise of common stock warrants	$ 0									$ 7,498,535
Exercisable warrant available price per share expiration period	2022-08
Issuance of unregistered warrants to purchase shares of common stock		1,434,639	2,160,000			1,163,526
Proceeds from issuance of common stock	$ 2,200,000
Exercise price of warrants	$ 1.50	$ 1.50	$ 2.50			$ 3.90
Roth Capital Partners, LLC and Feltl [Member]
Liquidity And Managements Plans [Line Items]
Proceeds from issuance of common stock, net of issuance costs				$ 9,000,000
Proceeds from exercise of common stock warrants					$ 564					7,500,000		$ 7,500,000
Proceeds from gross exercise of common stock warrants outstanding										$ 3,200,000
Exercisable warrant available price per share										$ 1.10
Exercisable warrant available price per share expiration period										2021-10
Issuance of unregistered warrants to purchase shares of common stock					9,100,000
Exercise price of warrants					$ 1.10
Shelf Registration Statement [Member]
Liquidity And Managements Plans [Line Items]
Aggregate offering price															$ 50,000,000
Minimum public float limit for offering															75,000,000
Proceeds from issuance of common stock, net of issuance costs			$ 8,600,000			$ 4,300,000
Proceeds from exercise of common stock warrants			0			0
Proceeds from gross exercise of common stock warrants outstanding			$ 5,400,000			$ 4,500,000
Exercisable warrant available price per share			$ 2.50			$ 3.90
Exercisable warrant available price per share expiration period			2022-10			2021-05
Issuance of unregistered warrants to purchase shares of common stock			2,160,000			1,163,526
Warrants exercise period description										Warrant proceeds remaining outstanding and available to be exercised at $2.50 per share until their expiration in October 2022.
Exercise price of warrants						$ 3.90
Minimum [Member]
Liquidity And Managements Plans [Line Items]
Unconditional purchase commitment, quarterly payment amount							$ 62,500
Maximum [Member] | Shelf Registration Statement [Member]
Liquidity And Managements Plans [Line Items]
Aggregate offering price															$ 50,000,000

Sales of Equity Securities - Ad

Sales of Equity Securities - Additional Information (Detail) - USD ($)	Aug. 11, 2017	Aug. 09, 2017	Mar. 31, 2017	Oct. 19, 2016	Oct. 14, 2016	May 04, 2016	Dec. 21, 2015	Sep. 30, 2017	Sep. 30, 2017	Dec. 31, 2016	Dec. 31, 2015	May 31, 2015
Class Of Stock [Line Items]
Increase in capital shares value										$ 1,400,000
Proceeds from issuance of common stock	$ 2,200,000
Common stock, shares issued								30,258,743	30,258,743	17,499,397
Common stock issuance costs										$ 79,000	$ 42,000
Issuance of unregistered warrants to purchase shares of common stock		1,434,639	2,160,000			1,163,526
Exercise price of warrants	$ 1.50	$ 1.50	$ 2.50			$ 3.90
Net cash proceeds from sale of securities		$ 2,000,000
Proceeds from exercise of common stock warrants	$ 0							$ 7,498,535
Exercisable warrant available price per share expiration period	2022-08
Common stock, par value								$ 0.0001	$ 0.0001	$ 0.0001
Roth Capital Partners, LLC, WestPark Capital and Chardan Capital [Member]
Class Of Stock [Line Items]
Public offering, number of shares issued			4,320,000
Stock price			$ 2.15
Placement agent agreement, effective date			Mar. 28, 2017
Issuance of unregistered warrants to purchase shares of common stock			2,160,000
Exercise price of warrants			$ 2.50
Issuance of warrants to purchase shares of common stock, grant date fair value			$ 2,800,000
Cost directly associated with offering			700,000
Net cash proceeds from sale of securities			8,600,000
Proceeds from exercise of common stock warrants			$ 0
Class of warrant or rights, expiration date			Oct. 1, 2022
Period of limitation to issue securities at variable rate			1 year
Roth Capital Partners, LLC and Feltl [Member]
Class Of Stock [Line Items]
Increase in capital shares value									$ 16,500,000
Overallotment issued to underwriter to purchase common stock, period					30 days
Public offering, number of shares issued					9,100,000
Stock price					$ 1.10
Issuance of unregistered warrants to purchase shares of common stock					9,100,000
Exercise price of warrants					$ 1.10
Class of warrant or rights, term					5 years
Issuance of warrants to purchase shares of common stock, grant date fair value					$ 5,200,000
Cost directly associated with offering				$ 1,000,000
Net cash proceeds from sale of securities				$ 9,000,000
Proceeds from exercise of common stock warrants					$ 564			$ 7,500,000	$ 7,500,000
Exercisable warrant available price per share expiration period								2021-10
Purchase of common stock by underwriters to cover overallotments, number of shares					627,131
Purchase of common stock by underwriters to cover overallotments, per share					$ 1.0331
Common stock, par value					$ 0.0009
Grant date fair values of overallotment options					$ 800,000
Roth Capital Partners, LLC and Feltl [Member] | Maximum [Member]
Class Of Stock [Line Items]
Purchase of common stock by underwriters to cover overallotments, number of shares					1,365,000
Issuance of overallotment options to purchase common stock shares					1,365,000
Shelf Registration Statement [Member]
Class Of Stock [Line Items]
Stock price						$ 3
Aggregate offering price												$ 50,000,000
Minimum public float limit for offering												75,000,000
Placement agent agreement, effective date						Apr. 25, 2016
Securities purchase agreement, effective date						Apr. 29, 2016
Public offering, number of common stock and warrants issued						1,662,191
Issuance of unregistered warrants to purchase shares of common stock			2,160,000			1,163,526
Exercise price of warrants						$ 3.90
Class of warrant or rights, term						5 years
Issuance of warrants to purchase shares of common stock, grant date fair value						$ 2,000,000
Cost directly associated with offering						700,000
Net cash proceeds from sale of securities			$ 8,600,000			4,300,000
Proceeds from exercise of common stock warrants			$ 0			0
Proceeds from gross exercise of common stock warrants outstanding						$ 4,500,000
Exercisable warrant available price per share expiration period			2022-10			2021-05
Shelf Registration Statement [Member] | Maximum [Member]
Class Of Stock [Line Items]
Aggregate offering price												$ 50,000,000
Common Stock Purchase Agreement [Member]
Class Of Stock [Line Items]
Proceeds from issuance of common stock										$ 544,051
Aggregate common stock shares purchase										173,145
Aspire Capital Fund, LLC [Member]
Class Of Stock [Line Items]
Common stock, shares issued							55,000
Ally Bridge [Member]
Class Of Stock [Line Items]
Stock price		$ 1.50
Proceeds from issuance of common stock		$ 2,200,000
Common stock issuance costs		200,000
Net cash proceeds from sale of securities		$ 2,000,000
Proceeds from exercise of common stock warrants	$ 0
Private offering, number of common stock and warrants issued		1,466,667
Issuance of warrants to purchase shares of common stock		1,434,639
Common Stock [Member] | Aspire Capital Fund, LLC [Member]
Class Of Stock [Line Items]
Increase in capital shares value							$ 15,000,000
Overallotment issued to underwriter to purchase common stock, period							30 months
Public offering, number of shares issued							208,334
Stock price							$ 4.80
Proceeds from issuance of common stock							$ 1,000,000

Fair Value Measurement - Additi

Fair Value Measurement - Additional Information (Detail) - USD ($) $ / shares in Units, $ in Millions	Aug. 09, 2017	Mar. 31, 2017	May 04, 2016
Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis [Line Items]
Issuance of unregistered warrants to purchase shares of common stock, grant date fair value	$ 1.5	$ 2.8	$ 2
Issuance of unregistered warrants to purchase shares of common stock	1,434,639	2,160,000	1,163,526
Warrants [Member]
Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis [Line Items]
Warrant exercise price	$ 1.03	$ 1.31

Fair Value Measurement - Assump

Fair Value Measurement - Assumptions Used for Determining Fair Values of Common Stock Warrants (Detail)	9 Months Ended
	Sep. 30, 2017$ / shares
March 31, 2017 Offering [Member]
Warrant Fair Value Black Scholes Method [Line Items]
Stock price	$ 2.13
Exercise price	$ 2.50
Expected dividend yield	0.00%
Discount rate-bond equivalent yield	1.93%
Expected life (in years)	5 years
Expected volatility	80.00%
August 9, 2017 Offering [Member]
Warrant Fair Value Black Scholes Method [Line Items]
Stock price	$ 1.39
Exercise price	$ 1.50
Expected dividend yield	0.00%
Discount rate-bond equivalent yield	1.81%
Expected life (in years)	5 years
Expected volatility	100.00%

Balance Sheet Details - Schedul

Balance Sheet Details - Schedule of Fixed Assets and Accrued Liabilities (Detail) - USD ($)	Sep. 30, 2017	Dec. 31, 2016
Fixed Assets
Machinery and equipment	$ 2,938,281	$ 2,728,468
Furniture and office equipment	147,976	143,726
Computer equipment and software	1,526,482	620,582
Leasehold improvements	550,246	517,968
Financed equipment	1,922,418	1,559,690
Construction in process	7,481	169,896
Total fixed assets, gross	7,092,884	5,740,330
Less accumulated depreciation and amortization	(4,173,088)	(3,933,999)
Total fixed assets, net	2,919,796	1,806,331
Accrued Liabilities
Accrued interest	324,406	20,776
Accrued payroll	477,889	168,727
Accrued vacation	503,380	364,953
Accrued bonuses	625,682	422,868
Accrued sales commissions	48,390	77,844
Current portion of deferred rent	106,418	67,085
Accrued other	88,220	37,783
Total accrued liabilities	$ 2,174,385	$ 1,160,036

April 2014 Credit Facility - Ad

April 2014 Credit Facility - Additional Information (Detail) - USD ($)	Aug. 09, 2017	Mar. 31, 2017	May 04, 2016	Apr. 30, 2014	Sep. 30, 2017	Dec. 31, 2014	Aug. 11, 2017	Jun. 28, 2017	Dec. 31, 2016	Jun. 30, 2016
Line of Credit Facility [Line Items]
Exercise price of unregistered warrants	$ 1.50	$ 2.50	$ 3.90				$ 1.50
Warrant term	5 years	5 years	5 years
Issuance of unregistered warrants to purchase shares of common stock, grant date fair value	$ 1,500,000	$ 2,800,000	$ 2,000,000
Oxford Finance LLC [Member]
Line of Credit Facility [Line Items]
Additional final payment to lender					$ 50,000
Total indebtedness and capital lease obligations outstanding								$ 3,000,000
Oxford Finance LLC [Member] | Common Stock [Member]
Line of Credit Facility [Line Items]
Warrant issued to lender				17,655
Exercise price of unregistered warrants				$ 14.16
Warrant term				10 years
Oxford Finance LLC [Member] | Minimum [Member]
Line of Credit Facility [Line Items]
Debt default limit amount				$ 250,000
Debt default final judgment amount				250,000
Oxford Finance LLC [Member] | First Term Loan [Member]
Line of Credit Facility [Line Items]
Net cash proceeds on term loan				4,898,000
Line of Credit Facility fees amount payable				$ 50,000
Line of Credit Facility, interest rate during period				7.95%
Percentage of final interest payment due at maturity				5.50%
Total indebtedness and capital lease obligations outstanding										$ 1,200,000
Issuance costs						$ 102,498
Net proceeds from credit facility						4,897,502
Issuance of unregistered warrants to purchase shares of common stock, grant date fair value						$ 233,107
Unamortized discounts					$ 54,405				$ 78,408
Effective annual interest rate					13.87%				13.87%
Total remaining principal payments due during fiscal year ending December 31, 2017					$ 498,132
Total remaining principal payments due during fiscal year ending December 31, 2018					$ 1,201,409
Oxford Finance LLC [Member] | Two Years [Member]
Line of Credit Facility [Line Items]
Term loan prepayment fee percentage				1.00%
Oxford Finance LLC [Member] | Scenario One [Member]
Line of Credit Facility [Line Items]
Line of Credit Facility, interest rate during period				7.95%
Oxford Finance LLC [Member] | Scenario Two [Member]
Line of Credit Facility [Line Items]
Line of Credit Facility, interest rate during period				7.71%

Equipment Financings - Addition

Equipment Financings - Additional Information (Detail)	Nov. 02, 2017USD ($)	Oct. 17, 2017USD ($)mo	Sep. 30, 2017USD ($)	Sep. 30, 2016USD ($)	Sep. 30, 2017USD ($)	Sep. 30, 2016USD ($)	Dec. 31, 2016USD ($)
Equipment Financings and Capital Lease Obligations [Line Items]
Financed equipment lease description					The Company leases certain laboratory equipment under arrangements accounted for as capital leases and classified as equipment financings. The financed equipment is depreciated on a straight-line basis over periods ranging from 5 to 7 years.
Financed equipment			$ 1,922,418		$ 1,922,418		$ 1,559,690
Accumulated depreciation related to financed equipment			681,000		681,000		$ 525,000
Fixed assets purchased as equipment financings					$ 362,729	$ 755,458
Equipment financings aggregate weighted average effective annual interest rate					13.79%		13.18%
Equipment financings maturity date on outstanding arrangements range, Start					2018-06
Equipment financings maturity date on outstanding arrangements range, End					2024-09
Present value of minimum lease payment due within one year			304,585		$ 304,585
Equipment Financings [Member]
Equipment Financings and Capital Lease Obligations [Line Items]
Depreciation expense related to financed equipment			$ 52,000	$ 40,000	$ 160,000	$ 93,000
Equipment Financings [Member] | Subsequent Event [Member]
Equipment Financings and Capital Lease Obligations [Line Items]
Total proceeds from equipment financing commitment	$ 150,848
Sale-leaseback transaction, aggregate gross value of fixed assets		$ 167,000
Sale-leaseback transaction, net book value of fixed assets		$ 156,000
Sale-leaseback transaction, annual interest rate		10.24%
Sale-leaseback transaction, frequency of payments		monthly
Sale-leaseback transaction, number of installments payments | mo		36
Sale-leaseback transaction, total amount to be repaid		$ 175,814
Sale-leaseback transaction, commitment period		2020-11
Minimum [Member] | Equipment Financings [Member]
Equipment Financings and Capital Lease Obligations [Line Items]
Financed equipment useful life					5 years
Maximum [Member] | Equipment Financings [Member]
Equipment Financings and Capital Lease Obligations [Line Items]
Financed equipment useful life					7 years

Equipment Financings - Schedule

Equipment Financings - Schedule of Remaining Future Minimum Lease Payments for Financed Equipment Obligations (Detail)	Sep. 30, 2017USD ($)
Capital Lease Obligations [Abstract]
2,017	$ 79,763
2,018	338,273
2,019	313,529
2,020	277,291
2,021	267,665
Thereafter	522,397
Total payments	1,798,918
Less amount representing interest	(544,210)
Present value of payments	1,254,708
2,017	8,954
2,018	58,355
2,019	68,925
2,020	54,768
2,021	48,802
Thereafter	88,313
Total payments	328,117
Present value of payments	$ 328,117

Stock-Based Compensation - Addi

Stock-Based Compensation - Additional Information (Detail)	May 31, 2017$ / sharesshares	May 02, 2017shares	Jul. 29, 2016$ / sharesshares	Jul. 25, 2016$ / sharesshares	Jul. 06, 2016USD ($)$ / sharesshares	Feb. 29, 2016$ / sharesshares	Aug. 31, 2015$ / sharesshares	Sep. 30, 2017USD ($)Plan$ / sharesshares	Sep. 30, 2016	Dec. 31, 2016USD ($)$ / sharesshares
Share Based Compensation Arrangement By Share Based Payment Award [Line Items]
Number of equity incentive plans | Plan								2
Total Shares Outstanding								2,484,286		896,662
Number of Shares, Granted								1,711,196
Weighted average exercise price per share | $ / shares								$ 1.49
Number of shares remaining forfeited								123,572
Unrecognized stock-based compensation expense, weighted-average recognition period								2 years 3 months 19 days
Minimum [Member]
Share Based Compensation Arrangement By Share Based Payment Award [Line Items]
Estimated forfeitures rate								0.00%	0.00%
Maximum [Member]
Share Based Compensation Arrangement By Share Based Payment Award [Line Items]
Estimated forfeitures rate								8.00%	8.00%
Stock Options [Member]
Share Based Compensation Arrangement By Share Based Payment Award [Line Items]
Intrinsic value of options outstanding | $								$ 5,507		$ 0
Intrinsic value of options vested and unvested expected to vest | $								$ 4,951
Stock options vested								229,501
Total weighted average grant date fair value | $ / shares								$ 5.40
Option awards assumptions, method used								Black-Scholes pricing model
Weighted-average estimated fair value of options granted | $ / shares								$ 1.03
Performance Stock Options [Member}
Share Based Compensation Arrangement By Share Based Payment Award [Line Items]
Percentage of Overall Stock Grant Subject to Vesting								100.00%
Performance RSUs [Member]
Share Based Compensation Arrangement By Share Based Payment Award [Line Items]
Percentage of Overall Stock Grant Subject to Vesting								100.00%
RSUs [Member]
Share Based Compensation Arrangement By Share Based Payment Award [Line Items]
Intrinsic value shares, RSUs outstanding | $								$ 443,932
Intrinsic value amount, RSUs unvested and vested expected to vest | $								$ 370,747
RSUs outstanding								360,920		174,249
Vested								10,920
Issuance of restricted stock units								350,000
Weighted-average estimated fair value of options granted | $ / shares								$ 1.87		$ 2.68
Stock Options and RSUs [Member]
Share Based Compensation Arrangement By Share Based Payment Award [Line Items]
Unrecognized stock-based compensation expense, stock options | $								$ 2,128,000
2013 Equity Incentive Plan [Member]
Share Based Compensation Arrangement By Share Based Payment Award [Line Items]
Total stock options and RSUs authorized				333,333
2013 Equity Incentive Plan [Member] | Chief Financial Officer [Member]
Share Based Compensation Arrangement By Share Based Payment Award [Line Items]
Weighted average exercise price per share | $ / shares				$ 1.95
Number of shares remaining forfeited								16,950
2013 Equity Incentive Plan [Member] | Stock Options [Member] | Chief Executive Officer [Member]
Share Based Compensation Arrangement By Share Based Payment Award [Line Items]
Weighted-average estimated fair value of options granted | $ / shares						$ 2.87	$ 4.40
Number of Shares, Granted						33,333	33,333
Weighted average exercise price per share | $ / shares						$ 4.02	$ 6.03
Number of shares remaining forfeited								50,333
2013 Equity Incentive Plan [Member] | Performance Stock Options granted on August 31, 2015 [Member] | Chief Executive Officer [Member]
Share Based Compensation Arrangement By Share Based Payment Award [Line Items]
Stock options vested								6,333
2013 Equity Incentive Plan [Member] | Performance Stock Options Granted on February 29, 2016 [Member] | Chief Executive Officer [Member]
Share Based Compensation Arrangement By Share Based Payment Award [Line Items]
Stock options vested								10,000
2013 Equity Incentive Plan [Member] | Performance Stock Options Granted on July 29 2016 [Member] | Chief Financial Officer [Member]
Share Based Compensation Arrangement By Share Based Payment Award [Line Items]
Stock options vested								16,383
2013 Equity Incentive Plan [Member] | Performance Stock Options [Member}
Share Based Compensation Arrangement By Share Based Payment Award [Line Items]
Weighted-average estimated fair value of options granted | $ / shares	$ 0.99
Weighted average exercise price per share | $ / shares	$ 1.50
2013 Equity Incentive Plan [Member] | Performance Stock Options [Member} | Chief Executive Officer [Member]
Share Based Compensation Arrangement By Share Based Payment Award [Line Items]
Number of Shares, Granted	200,000
2013 Equity Incentive Plan [Member] | Performance Stock Options [Member} | Chief Financial Officer [Member]
Share Based Compensation Arrangement By Share Based Payment Award [Line Items]
Number of Shares, Granted	100,000
2013 Equity Incentive Plan [Member] | Performance Stock Options [Member} | Employees and Executive Officers [Member]
Share Based Compensation Arrangement By Share Based Payment Award [Line Items]
Common stock, shares authorized		550,000
2013 Equity Incentive Plan [Member] | Performance Stock Options [Member} | Chief Scientific Officer and Senior Vice President [Member]
Share Based Compensation Arrangement By Share Based Payment Award [Line Items]
Number of Shares, Granted	75,000
2013 Equity Incentive Plan [Member] | Performance Stock Options [Member} | Senior Medical Director and Senior Vice President [Member]
Share Based Compensation Arrangement By Share Based Payment Award [Line Items]
Number of Shares, Granted	75,000
2013 Equity Incentive Plan [Member] | Time-Based RSUs [Member]
Share Based Compensation Arrangement By Share Based Payment Award [Line Items]
Vesting period								1 year
Weighted-average estimated fair value of options granted | $ / shares	$ 1.50
2013 Equity Incentive Plan [Member] | Time-Based RSUs [Member] | Chief Executive Officer [Member]
Share Based Compensation Arrangement By Share Based Payment Award [Line Items]
Issuance of restricted stock units	50,000
2013 Equity Incentive Plan [Member] | Time-Based RSUs [Member] | Executive Officer [Member]
Share Based Compensation Arrangement By Share Based Payment Award [Line Items]
Common stock, shares authorized		175,000
2013 Equity Incentive Plan [Member] | Time-Based RSUs [Member] | Other Executive Officer [Member]
Share Based Compensation Arrangement By Share Based Payment Award [Line Items]
Issuance of restricted stock units	25,000
2013 Equity Incentive Plan [Member] | Performance RSUs [Member]
Share Based Compensation Arrangement By Share Based Payment Award [Line Items]
Weighted-average estimated fair value of options granted | $ / shares	$ 1.50
2013 Equity Incentive Plan [Member] | Performance RSUs [Member] | Chief Executive Officer [Member]
Share Based Compensation Arrangement By Share Based Payment Award [Line Items]
Issuance of restricted stock units	25,000
2013 Equity Incentive Plan [Member] | Performance RSUs [Member] | Executive Officer [Member]
Share Based Compensation Arrangement By Share Based Payment Award [Line Items]
Common stock, shares authorized		175,000
2013 Equity Incentive Plan [Member] | Performance RSUs [Member] | Other Executive Officer [Member]
Share Based Compensation Arrangement By Share Based Payment Award [Line Items]
Issuance of restricted stock units	25,000
2013 Equity Incentive Plan [Member] | RSUs [Member] | Chief Financial Officer [Member]
Share Based Compensation Arrangement By Share Based Payment Award [Line Items]
Percentage of Overall Stock Grant Subject to Vesting				100.00%
Vesting period				1 year
Restricted stock units, grant date fair value | $ / shares				$ 1.95
Restricted stock unit award, shares				25,000
2013 Equity Incentive Plan [Member] | Retention RSUs [Member]
Share Based Compensation Arrangement By Share Based Payment Award [Line Items]
Vesting period					1 year
Restricted stock units, grant date fair value | $ / shares					$ 1.86
Restricted stock units, grant date fair value | $					$ 108,498
2013 Equity Incentive Plan [Member] | Retention RSUs [Member] | Chief Executive Officer [Member]
Share Based Compensation Arrangement By Share Based Payment Award [Line Items]
Issuance of restricted stock units					25,000
2013 Equity Incentive Plan [Member] | Retention RSUs [Member] | Executive Officer [Member]
Share Based Compensation Arrangement By Share Based Payment Award [Line Items]
Issuance of restricted stock units					58,332
2013 Equity Incentive Plan [Member] | Non-inducement Shares [Member]
Share Based Compensation Arrangement By Share Based Payment Award [Line Items]
Total stock options and RSUs authorized								3,522,955
Stock options and RSUs issued								2,712,157
Total Shares Outstanding								2,712,157
Common stock, shares authorized								638,487
Increase in number of shares of common stock authorized for issuance		2,500,000
2013 Equity Incentive Plan [Member] | Inducement shares [Member]
Share Based Compensation Arrangement By Share Based Payment Award [Line Items]
Total stock options and RSUs authorized								333,333
Stock options and RSUs issued								133,049
Total Shares Outstanding								133,049
Common stock, shares authorized								175,284
2013 Equity Incentive Plan [Member] | Options Vesting on One Year Anniversary [Member] | Chief Financial Officer [Member]
Share Based Compensation Arrangement By Share Based Payment Award [Line Items]
Total stock options and RSUs authorized				66,666
Weighted-average estimated fair value of options granted | $ / shares				$ 1.45
Percentage of Overall Stock Grant Subject to Vesting				25.00%
Vesting period				1 year
Stock option units remaining vesting period on Equal monthly basis				3 years
2013 Equity Incentive Plan [Member] | Options Vesting on Performance Achievement [Member] | Chief Financial Officer [Member]
Share Based Compensation Arrangement By Share Based Payment Award [Line Items]
Total stock options and RSUs authorized			33,333
Weighted-average estimated fair value of options granted | $ / shares			$ 1.26
2013 Equity Incentive Plan [Member] | Achievement of the Company's 2017 Corporate Goals [Member] | Performance Stock Options [Member} | Minimum [Member]
Share Based Compensation Arrangement By Share Based Payment Award [Line Items]
Percentage of Overall Stock Grant Subject to Vesting								70.00%
2013 Equity Incentive Plan [Member] | Achievement of the Company's 2017 Corporate Goals [Member] | Performance RSUs [Member] | Minimum [Member]
Share Based Compensation Arrangement By Share Based Payment Award [Line Items]
Percentage of Overall Stock Grant Subject to Vesting								70.00%

Stock-Based Compensation - Summ

Stock-Based Compensation - Summary of Stock Option Activity (Detail) - $ / shares	9 Months Ended	12 Months Ended
	Sep. 30, 2017	Dec. 31, 2016
Disclosure Of Compensation Related Costs Sharebased Payments [Abstract]
Number of Shares Outstanding, Beginning Balance	896,662
Number of Shares, Granted	1,711,196
Number of Shares, Cancelled/forfeited/expired	(123,572)
Number of Shares Outstanding, Ending Balance	2,484,286	896,662
Number of Shares, Vested and unvested expected to vest, Ending Balance	2,267,826
Weighted Average Exercise Price Per Share, Outstanding, Beginning Balance	$ 8.80
Weighted Average Exercise Price Per Share, Granted	1.49
Weighted Average Exercise Price Per Share, Cancelled/forfeited/expired	5.13
Weighted Average Exercise Price Per Share, Outstanding, Ending Balance	3.93	$ 8.80
Weighted Average Exercise Price Per Share, Vested and unvested expected to vest, Ending Balance	$ 4.16
Weighted Average Remaining Contractual Term in Years, Outstanding	8 years 10 months 25 days	8 years 6 months
Weighted Average Remaining Contractual Term in Years, Cancelled/forfeited/expired	8 years 8 months 12 days
Weighted Average Remaining Contractual Term in Years, Vested and unvested expected to vest	8 years 9 months 18 days

Stock-Based Compensation - Assu

Stock-Based Compensation - Assumptions Used for Determining Fair Value of Stock Options Under Black-Scholes Pricing Model (Detail)	9 Months Ended
	Sep. 30, 2017$ / shares
Share Based Compensation Arrangement By Share Based Payment Award [Line Items]
Expected dividend yield	0.00%
Minimum [Member]
Share Based Compensation Arrangement By Share Based Payment Award [Line Items]
Stock and exercise prices	$ 1.22
Discount rate-bond equivalent yield	1.79%
Expected life (in years)	5 years 1 month 13 days
Expected volatility	70.00%
Maximum [Member]
Share Based Compensation Arrangement By Share Based Payment Award [Line Items]
Stock and exercise prices	$ 2.13
Discount rate-bond equivalent yield	2.08%
Expected life (in years)	6 years 1 month 2 days
Expected volatility	90.00%

Stock-Based Compensation - Sche

Stock-Based Compensation - Schedule of Percentage Of Overall Performance Grant Subject To Vesting (Detail)	9 Months Ended
	Sep. 30, 2017
Performance Stock Options [Member}
Share Based Compensation Arrangement By Share Based Payment Award [Line Items]
Percentage of Overall Stock Grant Subject to Vesting	100.00%
Performance Stock Options [Member} | 2013 Equity Incentive Plan [Member] | Minimum Revenue [Member]
Share Based Compensation Arrangement By Share Based Payment Award [Line Items]
Percentage of Overall Stock Grant Subject to Vesting	20.00%
Performance Stock Options [Member} | 2013 Equity Incentive Plan [Member] | Cost of Revenue Reductions And Improvements [Member]
Share Based Compensation Arrangement By Share Based Payment Award [Line Items]
Percentage of Overall Stock Grant Subject to Vesting	15.00%
Performance Stock Options [Member} | 2013 Equity Incentive Plan [Member] | Increase Cash Generated From Operations [Member]
Share Based Compensation Arrangement By Share Based Payment Award [Line Items]
Percentage of Overall Stock Grant Subject to Vesting	15.00%
Performance Stock Options [Member} | 2013 Equity Incentive Plan [Member] | Minimum Cash On-Hand at December 31, 2017 [Member]
Share Based Compensation Arrangement By Share Based Payment Award [Line Items]
Percentage of Overall Stock Grant Subject to Vesting	15.00%
Performance Stock Options [Member} | 2013 Equity Incentive Plan [Member] | Minimum Customer Agreements, Product Licensing And Product Launch [Member]
Share Based Compensation Arrangement By Share Based Payment Award [Line Items]
Percentage of Overall Stock Grant Subject to Vesting	20.00%
Performance Stock Options [Member} | 2013 Equity Incentive Plan [Member] | Implementation Of New Products And Utility Trials [Member]
Share Based Compensation Arrangement By Share Based Payment Award [Line Items]
Percentage of Overall Stock Grant Subject to Vesting	15.00%
Performance RSUs [Member]
Share Based Compensation Arrangement By Share Based Payment Award [Line Items]
Percentage of Overall Stock Grant Subject to Vesting	100.00%
Performance RSUs [Member] | 2013 Equity Incentive Plan [Member] | Minimum Revenue [Member]
Share Based Compensation Arrangement By Share Based Payment Award [Line Items]
Percentage of Overall Stock Grant Subject to Vesting	20.00%
Performance RSUs [Member] | 2013 Equity Incentive Plan [Member] | Cost of Revenue Reductions And Improvements [Member]
Share Based Compensation Arrangement By Share Based Payment Award [Line Items]
Percentage of Overall Stock Grant Subject to Vesting	15.00%
Performance RSUs [Member] | 2013 Equity Incentive Plan [Member] | Increase Cash Generated From Operations [Member]
Share Based Compensation Arrangement By Share Based Payment Award [Line Items]
Percentage of Overall Stock Grant Subject to Vesting	15.00%
Performance RSUs [Member] | 2013 Equity Incentive Plan [Member] | Minimum Cash On-Hand at December 31, 2017 [Member]
Share Based Compensation Arrangement By Share Based Payment Award [Line Items]
Percentage of Overall Stock Grant Subject to Vesting	15.00%
Performance RSUs [Member] | 2013 Equity Incentive Plan [Member] | Minimum Customer Agreements, Product Licensing And Product Launch [Member]
Share Based Compensation Arrangement By Share Based Payment Award [Line Items]
Percentage of Overall Stock Grant Subject to Vesting	20.00%
Performance RSUs [Member] | 2013 Equity Incentive Plan [Member] | Implementation Of New Products And Utility Trials [Member]
Share Based Compensation Arrangement By Share Based Payment Award [Line Items]
Percentage of Overall Stock Grant Subject to Vesting	15.00%

Stock-Based Compensation - Su44

Stock-Based Compensation - Summary of RSU Activity (Detail) - RSUs [Member]	9 Months Ended
	Sep. 30, 2017$ / sharesshares
Share Based Compensation Arrangement By Share Based Payment Award [Line Items]
Number of Shares Outstanding, Beginning Balance | shares	174,249
Number of Shares, Granted | shares	350,000
Number of share, Vested and issued | shares	(155,829)
Number of share, Forfeited | shares	(7,500)
Number of Shares Outstanding, Ending Balance | shares	360,920
Number of Shares, Vested and unvested expected to vest, Ending Balance | shares	301,420
Weighted Average Grant Date Fair Value, Outstanding, Beginning Balance | $ / shares	$ 2.68
Weighted Average Grant Date Fair Value, Granted | $ / shares	1.50
Weighted Average Grant Date Fair Value, Vested and issued | $ / shares	1.96
Weighted Average Grant Date Fair Value, Forfeited | $ / shares	2.12
Weighted Average Grant Date Fair Value, Outstanding, Ending Balance | $ / shares	1.87
Weighted Average Grant Date Fair Value, Vested and unvested expected to vest, Ending Balance | $ / shares	$ 1.95

Stock-Based Compensation - Effe

Stock-Based Compensation - Effects of Stock-Based Compensation Related to Equity Awards to Employees and Nonemployees on Condensed Statement of Operations and Comprehensive Loss (Detail) - USD ($)	3 Months Ended		9 Months Ended
	Sep. 30, 2017	Sep. 30, 2016	Sep. 30, 2017	Sep. 30, 2016
Stock Options [Member]
Share Based Compensation Arrangement By Share Based Payment Award [Line Items]
Total stock-based compensation	$ 331,977	$ 406,613	$ 883,672	$ 1,097,439
Stock Options [Member] | Cost of revenues [Member]
Share Based Compensation Arrangement By Share Based Payment Award [Line Items]
Total stock-based compensation	59,720	34,119	133,105	89,606
Stock Options [Member] | Research and Development Expenses [Member]
Share Based Compensation Arrangement By Share Based Payment Award [Line Items]
Total stock-based compensation	53,405	28,189	121,834	87,153
Stock Options [Member] | General and Administrative Expenses [Member]
Share Based Compensation Arrangement By Share Based Payment Award [Line Items]
Total stock-based compensation	178,671	292,381	528,406	829,516
Stock Options [Member] | Sales and Marketing Expenses [Member]
Share Based Compensation Arrangement By Share Based Payment Award [Line Items]
Total stock-based compensation	40,181	51,924	100,327	91,164
RSUs [Member]
Share Based Compensation Arrangement By Share Based Payment Award [Line Items]
Total stock-based compensation	475,688	465,269	1,232,149	1,164,979
RSUs [Member] | Cost of revenues [Member]
Share Based Compensation Arrangement By Share Based Payment Award [Line Items]
Total stock-based compensation	20,417	14,918	58,717	16,834
RSUs [Member] | Research and Development Expenses [Member]
Share Based Compensation Arrangement By Share Based Payment Award [Line Items]
Total stock-based compensation	20,418	14,131	57,490	15,583
RSUs [Member] | General and Administrative Expenses [Member]
Share Based Compensation Arrangement By Share Based Payment Award [Line Items]
Total stock-based compensation	74,521	6,668	160,927	7,676
RSUs [Member] | Sales and Marketing Expenses [Member]
Share Based Compensation Arrangement By Share Based Payment Award [Line Items]
Total stock-based compensation	$ 28,355	$ 22,939	$ 71,343	$ 27,447

Common Stock Warrants Outstan46

Common Stock Warrants Outstanding - Summary of Equity-Classified Common Stock Warrant Activity (Detail) - Warrants [Member] - $ / shares	Mar. 31, 2017	Sep. 30, 2017	Dec. 31, 2016
Class Of Warrant Or Right [Line Items]
Number of Shares, Outstanding, Beginning Balance		11,623,957
Number of Shares, Issued	2,160,000	3,594,639
Number of Shares, Exercised		(6,816,850)
Number of Shares, Outstanding, Ending Balance		8,401,746	11,623,957
Weighted Average Exercise Price Per Share, Outstanding, Beginning Balance		$ 1.93
Weighted Average Exercise Price Per Share, Issued		2.10
Weighted Average Exercise Price Per Share, Exercised		1.10
Weighted Average Exercise Price Per Share, Outstanding, Ending Balance		$ 2.68	$ 1.93
Average Remaining Contractual Term (in years)		4 years 2 months 12 days	4 years 7 months 6 days

Common Stock Warrants Outstan47

Common Stock Warrants Outstanding - Additional Information (Detail) - USD ($)	Mar. 31, 2017	Sep. 30, 2017
Class Of Warrant Or Right [Line Items]
Common stock warrants outstanding, intrinsic value		$ 378,337
Warrants [Member]
Class Of Warrant Or Right [Line Items]
Warrants issued	2,160,000	3,594,639
Warrants exercisable period		5 years
Warrants exercisable commencing date		Oct. 1, 2017

Net Loss per Common Share - Add

Net Loss per Common Share - Additional Information (Detail)	Sep. 29, 2016
Earnings Per Share [Abstract]
Reverse stock split of common shares outstanding	0.33

Net Loss per Common Share - Sch

Net Loss per Common Share - Schedule of Anti-Dilutive Securities Excluded from Computations of Diluted Weighted-Average Shares (Detail) - shares	3 Months Ended		9 Months Ended
	Sep. 30, 2017	Sep. 30, 2016	Sep. 30, 2017	Sep. 30, 2016
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]
Anti-dilutive common share equivalents	11,247,481	3,000,712	11,247,481	3,000,712
Warrants Outstanding [Member]
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]
Anti-dilutive common share equivalents	8,401,746	1,896,826	8,401,746	1,896,826
RSUs Outstanding [Member]
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]
Anti-dilutive common share equivalents	360,920	176,749	360,920	176,749
Preferred Warrants Outstanding [Member]
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]
Anti-dilutive common share equivalents	529	529	529	529
Common Options Outstanding [Member]
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]
Anti-dilutive common share equivalents	2,484,286	926,608	2,484,286	926,608

Commitments and Contingencies -

Commitments and Contingencies - Additional Information (Detail) - USD ($)	Nov. 02, 2017	Feb. 29, 2016	Sep. 30, 2017
Loss Contingencies [Line Items]
Unconditional purchase commitment aggregate amount		$ 1,062,500	$ 625,000
Unconditional purchase commitment payment terms			Quarterly
Unconditional purchase commitment period			May 31, 2020
Total payments for future sales tax and maintenance obligations			$ 328,117
Equipment Financing [Member] | Subsequent Event [Member]
Loss Contingencies [Line Items]
Total proceeds from equipment financing commitment	$ 150,848
Minimum [Member]
Loss Contingencies [Line Items]
Unconditional purchase commitment, quarterly payment amount		$ 62,500

Related Party Transactions - Ad

Related Party Transactions - Additional Information (Detail)	Aug. 11, 2017USD ($)	Feb. 01, 2017	Oct. 31, 2016USD ($)DirectorConsultantshares	May 04, 2016USD ($)Directorshares	Sep. 30, 2017USD ($)ft²	Sep. 30, 2016USD ($)	Mar. 31, 2015	Sep. 30, 2017USD ($)ft²	Sep. 30, 2016USD ($)	Dec. 31, 2016USD ($)
Related Party Transaction [Line Items]
Rental income					$ 12,804	$ 38,412		$ 51,216	$ 115,236
Proceeds from issuance of common stock	$ 2,200,000
Number of consultants | Consultant			1
San Diego California Facility [Member]
Related Party Transaction [Line Items]
Lease expiration date		Mar. 31, 2017
Rental income								51,216	$ 115,236
Aegea Biotechnologies, Inc [Member]
Related Party Transaction [Line Items]
Reimbursement for shared patent costs								$ 15,325		$ 19,047
Nonexecutive [Member] | San Diego California Facility [Member]
Related Party Transaction [Line Items]
Leased facility, expansion of original premises | ft²					9,849			9,849
Lease agreement date of commencement								Mar. 30, 2015
Leased facility, rent expense per month								$ 12,804
Lease facility, refundable security deposit amount					$ 12,804			$ 12,804
Lease expiration date							Jul. 31, 2015
Lease agreement, amount of security deposit applied against additional rents owed					16,000
Lease agreement, amount of additional rents waived					$ 3,200
Director [Member]
Related Party Transaction [Line Items]
Number of members of board of directors | Director			3	3
Initial public offering, number of shares issued | shares			534,088	58,335
Issuance of warrants to purchase shares of common stock | shares			534,088	40,832
Proceeds from issuance of common stock			$ 587,497	$ 175,000
Director [Member] | Chief Executive Officer [Member]
Related Party Transaction [Line Items]
Number of members of board of directors | Director			7
Claire K.T. Reiss [Member]
Related Party Transaction [Line Items]
Initial public offering, number of shares issued | shares			227,272	204,758
Issuance of warrants to purchase shares of common stock | shares			227,272	143,330
Proceeds from issuance of common stock			$ 249,999	$ 614,273
Beneficial owner percentage of company's common stock			10.00%	10.00%
Consultants [Member]
Related Party Transaction [Line Items]
Initial public offering, number of shares issued | shares			79,090
Issuance of warrants to purchase shares of common stock | shares			79,090
Proceeds from issuance of common stock			$ 86,999

Subsequent Events - Additional

Subsequent Events - Additional Information (Detail)	Nov. 02, 2017USD ($)
Equipment Financings [Member] | Subsequent Event [Member]
Subsequent Event [Line Items]
Total proceeds from equipment financing commitment	$ 150,848